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Abstract 
Inflammation is a key factor in multiple diseases including primary immune-mediated 
inflammatory diseases e.g. rheumatoid arthritis but also, less obviously, in many 
other common conditions, e.g. cardiovascular disease and diabetes. Together, 
chronic inflammatory diseases contribute to the majority of global morbidity and 
mortality. However, our understanding of the underlying processes by which the 
immune response is activated and sustained is limited by a lack of cellular and 
molecular information obtained in situ. Molecular imaging is the visualization, 
detection and quantification of molecules in the body. The ability to reveal 
information on inflammatory biomarkers, pathways and cells can improve disease 
diagnosis, guide and monitor therapeutic intervention and identify new targets for 
research. The optimum molecular imaging modality will possess high sensitivity and 
high resolution and be capable of non-invasive quantitative imaging of multiple 
disease biomarkers while maintaining an acceptable safety profile. The mainstays of 
current clinical imaging are computed tomography (CT), magnetic resonance 
imaging (MRI), ultrasound (US) and nuclear imaging such as positron emission 
tomography (PET). However, none of these have yet progressed to routine clinical 
use in the molecular imaging of inflammation, therefore new approaches are 
required to meet this goal. This review sets out the respective merits and limitations 
of both established and emerging imaging modalities as clinically useful molecular 
imaging tools in addition to potential theranostic applications. 
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1. Introduction 
1.1 Definition of molecular imaging 
Molecular imaging concerns the visualization, detection and quantification of 
physiological and pathologic / disease processes in the body at the cellular or 
molecular level. To reach such a level of detailed imaging requires specialized 
instruments (modalities) that either alone or in combination with imaging agents 
(either targeted or passive) can uncover the status of a tissue via detection of 
biochemical or other molecular markers, particularly in the context of a disease state. 
One of the major aims of molecular imaging is to answer questions of disease 
processes that are beyond current diagnostic methods. The need is to image 
biochemical processes in intact living organisms over time in a minimally- or non-
invasive manner. As such, molecular imaging has the potential to transform each 
aspect of medical care including improved and earlier diagnosis, more accurate 
monitoring of therapy, identifying novel drug targets/drug validation and helping to 
understand the complex biochemical pathways that interact to create disease states. 
 
1.2 The requirement for molecular imaging of inflammation in modern 
medicine 
We now know that inflammation is a key or major contributing factor in many chronic 
diseases including cardiovascular disease (CVD), rheumatoid arthritis (RA), 
inflammatory bowel disease (IBD), colitis, systemic lupus erythematosus (SLE), 
diabetes, multiple sclerosis (MS) and Alzheimer’s disease and is closely related to 
many aspects of tumor progression. These conditions contribute a significant 
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proportion of worldwide morbidity and mortality and cause substantial socioeconomic 
burdens on society (Mathers and Loncar, 2006; Jacobs et al., 2011). 
Although new therapies have brought significant improvements to patient care, a 
considerable portion of patients still lack sufficient therapeutic effect and incidence of 
complications remains high, which is often a by-product of the non-specific nature of 
the treatments provided. There is also a lack of tailoring of drugs to individual patient 
needs, which is especially important in chronic pathologies that may present with 
different underlying causes or have distinct clinical stages, each defined by a specific 
inflammatory environment. We briefly take RA as an example of where a more 
sophisticated understanding at the molecular level could improve patient care. RA is 
a disease that affects 0.5-1% of the global population - treatment options are 
significantly greater than for many other chronic inflammatory conditions. Approved 
biological therapies for RA, principally anti-TNF antibodies, were a revolutionary 
breakthrough in advancing RA treatment, adding to the established broad ranging 
anti-inflammatory treatments such as methotrexate, yet much is still unknown about 
the drug-disease interactions such as why some patients respond to anti-TNF more 
than others or why there is frequently a dissociation between clinical scoring and 
destructive joint progression (Smolen et al., 2016). It is also recognized that early 
diagnosis followed by rapid administration of appropriate therapy is the ideal strategy 
for treating inflammatory RA and improving patient outlook, yet early diagnosis is 
challenging due to early symptoms going undiagnosed or not being present at all. 
Studies of pre-clinical RA include individuals with positive autoantibodies and 
marginally raised inflammatory markers with no visible clinical features (Firestein and 
McInnes, 2017). This prodromal period can precede the disease for a decade and 
poses a significant clinical and therapeutic challenge, which could be transformed by 
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better molecular imaging to guide early clinical decision. Currently, clinicians 
determine disease presence/severity based on several factors: symptoms, 
detectable disease biomarkers and medical imaging results. The advent of biological 
therapies targeting inflammatory molecules such as cytokines can, in turn, also lead 
to new diagnostic approaches with the addition of imaging agents to the targeted 
antibody allowing visualization of the cytokine concentration in the disease site and 
to assess whether the unlabeled antibody could be of benefit therapeutically. 
Information gained from such an approach may also help answer why certain 
patients are non-responders to a cytokine-targeted therapy. In comparison with 
cancer, inflammatory diseases such as RA involve multiple tissues and it is yet 
unexplored if there is considerable mismatch between disease and treatment 
distribution in the body. Studies exploring lymph node, bone marrow and synovial 
tissue biopsies would further support the systemic distribution of the disease (van 
Baarsen et al., 2013). Hence, the ability to visualize disease potentiating molecules 
can inform clinicians in diagnosis, treatment monitoring and in deciding whether or 
not a potential therapy may be beneficial (Malviya et al., 2013). 
A final point worth noting is that each disease typically has a specific treatment 
regime which traditionally has ignored potentially common underlying inflammatory 
components between different diseases that have a strong immune component. This 
includes the role of inflammation in cancer (Grivennikov et al., 2010), and the inter-
relationships between RA and CVD (Mason and Libby, 2015) or chronic obstructive 
pulmonary disease (COPD) and stroke (Austin et al., 2016). Indeed, adverse 
cardiovascular events are increased in RA patients and are subsequently reduced 
following introduction of anti-inflammatory therapies although the inflammatory 
mediators linking these two diseases are unclear (Tocci et al., 2016). These 
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unanswered questions are a result of a lack of understanding of the precise cellular 
and molecular inflammatory mechanisms that drive each particular pathology (Tabas 
and Glass, 2013). Ultimately, inflammatory processes are finely tuned systems, with 
many molecular signals that orchestrate the immune response. For most conditions, 
it is probable that only limited diagnostic information will be obtained by one or two 
blood-derived inflammatory markers. The potential strength of molecular imaging is 
to ‘see’ into the core of the inflammatory site, targeting multiple biomarkers 
(multiplexing) to provide a deeper insight into the triggers, cellular interplay, pro- 
versus anti-inflammatory mediators and the ability to evaluate current and the next 
generation of therapies for chronic immune diseases with a level of precision and 
detail not seen before. Implementing molecular imaging, therefore, can uncover new 
information on disease processes which can in turn offer new targets for disease 
diagnosis and stratification. In this sense, molecular imaging could confer a discipline 
defining transition in the next decade with profound potential to revolutionize the 
management of patients with chronic diseases. 
 
2. Molecular imaging modalities 
2.1 Overview 
The mainstays of current clinical imaging are computed tomography (CT), magnetic 
resonance imaging (MRI), ultrasound (US) and the nuclear imaging modalities: 
positron emission tomography (PET)/single photon emission tomography (SPECT). 
These imaging techniques have transformed medical imaging in improving disease 
detection, progression and therapeutic assessment across a wide spectrum of 
diseases from oncology and CVD to rheumatic musculoskeletal diseases and 
neurodegenerative conditions. In patients, these modalities are primarily used for 
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anatomic and functional imaging at the tissue level, although at least for PET, 
molecular imaging is being realized, despite significant shortcomings as will be 
detailed throughout this report. However, they retain inherent weaknesses that 
preclude the combined high sensitivity, high resolution, and simultaneous detection 
of multiple biomarkers in a non-invasive manner that is the ultimate goal of molecular 
imaging research. 
Other techniques that potentially offer greater promise as molecular imaging tools 
include mostly pre-clinical stage technologies such as optical imaging including 
photoacoustics as well as techniques classified as vibrational spectroscopy which 
includes Raman spectroscopy and surface-enhanced-Raman spectroscopy (SERS). 
While pre-clinical technologies such as near-infrared fluorescence (NIRF) with 
quantum dots and spectral imaging using SERS can allow a high level of 
multiplexing, these are not yet clinic ready. There exists, therefore, a broad range of 
established and emerging technologies with molecular imaging potential and these 
will be described and compared, with examples of use relating to inflammation 
imaging highlighted. Additionally, for each imaging modality, we offer a section 
dedicated to potential therapeutic use of the technology in modifying disease 
processes, for example through using imaging agents loaded with anti-inflammatory 
drugs. Finally, there will be an assessment of the relative strengths and weaknesses 
of each technique as a tool for molecular imaging and their prospective use within 
the clinic. 
 
2.2 Imaging agents 
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Molecular imaging can rely on either direct detection of endogenous molecules or 
employ exogenous tracers (passive or ligand targeted) that are tailored to a 
particular modality of choice e.g. fluorescent probes for near-infrared (NIR) optical 
imaging or radiolabeled tracers for PET/SPECT imaging. Traditionally, exogenous 
tracers have been small molecules <2 kDa (<4 nm) in size (e.g. iodinated 
compounds for CT, chelated gadolinium for MRI and 18F-FDG for PET). Despite 
providing significant advances in diagnosing disease, particularly in the field of 
oncology, small molecule tracers have important limitations with regard to molecular 
imaging owing to their rapid clearance, lack of adaptation to allow detection via 
imaging, potential toxicity and relatively poor signal strength. These limitations have 
led to development of novel materials to overcome the limitations of current 
diagnostic molecular imaging and to cater for the new technologies that are 
emerging, particularly within the optical and vibrational imaging fields. Indeed, for 
several imaging modalities such as magnetic particle imaging (MPI) and SERS, 
nanocarriers (or nanoparticles (NPs) as they will be referred to throughtout the 
remainder of this review) are an essential component for signal induction. In 
comparison to small molecules, NPs offer a high level of control over design (e.g. 
contrast agent class/dose, body residence times, targeting ligands, drug delivery). 
NPs are small nanomaterials, less than 1 µM, that can be composed of a diverse 
range of materials depending on the requirements of the modality and desired 
residence times. NPs offer the following advantages over small molecules: 1) They 
can carry a high quantity of tracer to the site of interest (such as bismuth or gold for 
CT) in a protective shell, creating a concentrated signal to improve sensitivity 
coupled with reduced toxicity, assuming the elimination kinetics of the NPs are 
carefully understood; 2) They can be engineered to various specifications to increase 
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circulation/residence times allowing stable longitudinal imaging; 3) Can be used for 
passive uptake into tissues via the enhanced permeability and retention (EPR) effect 
or can be functionalized with biomolecules such as antibodies, peptides or aptamers 
targeted to a disease related biomarker of interest; 4) The large surface area allows 
many targeting ligands to be attached to a single NP which increases the binding 
capacity compared with single molecules. Indeed, this increased binding can be 
quite substantial, ranging from 1-2 orders of magnitude to as high as 5-6 orders of 
magnitude (Hong et al., 2007; Benezra et al., 2011); 5) The adaptability of NPs to a 
particular modality coupled with an ability to create multiple ‘ flavors’ of NPs (NPs 
targeted to different in vivo targets) allows high multiplexing potential. The ability to 
simultaneously measure multiple biomarkers (Table 1) within the same acquisition 
window is the key to diagnostic molecular imaging, particularly within the context of 
inflammation imaging when a single inflammatory marker is insufficient to provide a 
clinician with the information to diagnose/stratify a disease, particularly when 
pathological changes may be minimal; 6) Can be engineered to be multi-modal (the 
detection of one NP by two or more imaging modalities); 7) Can offer novel 
theranostic strategies e.g. by providing a high sensitivity imaging signal coupled with 
delivering a drug payload. 
 
2.3 Hybrid imaging platforms 
As observed in the last 2 decades, it is unlikely that one single imaging modality will 
possess all the required attributes (high spatial resolution, high sensitivity, low 
toxicity, fast scan times, consistent quantification, deep tissue imaging, strong 
multiplexing etc.) for clinical molecular imaging. Indeed, with common imaging 
modalities, there is currently an inverse correlation between sensitivity and spatial 
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resolution. These limitations have led to the engineering of hybrid technologies, 
many of which are now commonplace such as PET/CT, SPECT/CT and the re-
emergence of PET/MRI, all of which are being investigated for molecular imaging 
potential. Pre-clinically, there is also a push towards multi-modal imaging, such as 
combining two or more optical imaging technologies onto a single probe, or NIRF 
combined with intravascular ultrasound (IVUS) or even single multi -modal NPs that 
are amenable to multiple imaging systems, for example a NP with an iron oxide core 
functionalized via a dextran coating to fluorophores for optical imaging (Wolfbeis et 
al., 2015). This report will describe recent developments in hybrid imaging systems 
using established imaging modalities in the molecular imaging space and the 
potential of more early stage pre-clinical multi-modal imaging systems and their route 
to clinical translation. 
 
2.4 Computed tomography (CT) 
CT has been a mainstay medical imaging technique since its inception in the 1970s, 
superseding older X-ray technologies, owing to its greater power in creating 3D 
anatomical imaging through computational algorithms as opposed to classical 2D X-
ray imaging. CT operates with relatively good spatial resolution, at least for 
anatomical imaging needs (Brenner, 2010). CT can readily distinguish electron-
dense structures such as bone and teeth from electron-poor structures such as soft 
tissues making it an excellent modality for anatomical imaging of skeletal structures. 
Inherent advantages include fast scan times and body wide imaging. In the absence 
of a contrast agent, discrimination of anatomical tissues can be challenging 
(Cormode et al., 2014). The most common contrast agents are iodine-based 
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compounds which have found particular use in coronary artery imaging including 
Coronary Computed Tomography Angiography (CCTA). 
Clinical use 
CT is primarily an anatomical imaging technique, limited by its low sensitivity, an 
inability to accurately discriminate soft tissue structures and to accurately quantify 
contrast agents (Anderson et al., 2014). While the advent of dual energy CT (DECT) 
has greatly improved the technology, clinical advancement has mainly been realized 
via enhanced detection of lesions, such as in the fields of oncology and CVD. 
Indeed, CT’s main use in CVD has been calcium scoring of plaques to assess 
atherosclerotic plaque burden and CT calcium scoring is widely practiced for risk 
stratification within the clinic, although calcification is a product of late-stage 
pathology limiting its potential in diagnosis of early stage lesions (Sandfort et al., 
2015). CT has not progressed clinically to the level of true molecular imaging either 
in oncology, CVD (the two major drivers of CT technology) or other conditions and 
the inherent low sensitivity, lack of approved tracers and concerns over toxicity 
means clinical molecular inflammation imaging is lacking. 
Pre-clinical use and in-human trials 
Micro-computed tomography or "micro-CT" is similar in principle to standard CT but 
on a smaller scale and with superior resolution and is frequently employed in pre-
clinical research. Micro-CT produces high resolution (typically 15-50 µM in pre-
clinical studies) (MI Bioresearch Inc.; Biolaurus Inc.) although some in vivo systems 
offer better performance still. Micro-CT scanners are employed, both in vivo and ex 
vivo, typically to measure hard tissue structures. Modifications of micro-CT utilizing 
ionic iodine contrast have been used to measure glycosaminoglycans (GAGs), a 
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major component of healthy joint cartilage with an inverse relationship existing for 
joint iodine concentration and cartilage density (Palmer et al., 2006) and such an 
approach has been used to measure cartilage growth in rats (Xie et al., 2009a). 
Multicolor or spectral CT can differentiate several compounds based on each 
compound’s specific energy-dependent X-ray absorption profile. One such spectral-
CT imaging system (MARS small bore scanner; MARS Bioimaging Ltd) has been 
used to image an excised human tibial plateau (break of tibia bone at knee joint) with 
discrimination of different joint components possible in a proof of concept study 
(Rajendran et al., 2017). Spectral CT potentially overcomes some of the obstacles of 
clinical level CT and MRI in combining fast, high resolution scanning with more 
accurate tissue resolution and quantification of contrast enhanced areas but requires 
further refinements to be a viable clinical tool (Ragendran et al., 2017). Translating 
this to clinical osteoarthritis use would require utilizing the ionic iodine spectral CT to 
measure disease progression and/or response to therapy. It is worth noting; 
however, that radiation dose was not measured in this study and remains a key 
concern with high resolution CT imaging. Attempts using the MARS spectral-CT 
system have also been employed with a view to advancing spectral-CT imaging of 
the atherosclerotic plaque. Using this technology on excised human plaques, 
spectral-CT was able to differentiate multiple plaque components in human tissue 
sections within the same voxel including lipid, calcium/iron and water containing 
components with the caveats that high radiation doses were used and calcium and 
iron could not be distinguished within the same voxel (Zainon et al., 2012). Cormode 
et al., 2010 employed gold NPs targeted to macrophages (Au-HDL) together with an 
iodinated contrast emulsion agent for imaging small vessels in addition to 
endogenous calcium for spectral-CT in apolipoprotein-E (apoE)-/- mice, the gold-
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standard model for the study of experimental atherosclerosis. Specific uptake by 
macrophages in plaque regions was evident and the gold signal could be 
discriminated from iodine and calcium allowing simultaneous imaging of multiple 
plaque components (Cormode et al., 2010). Pre-clinical development of NPs as CT 
imaging agents has also progressed - albeit at a much slower and limited rate 
compared with other modalities such as MRI and PET - with the aim of targeting 
inflammation in atherosclerosis. An iodinated NP contrast agent, N1177, was 
developed with the intention of specifically targeting macrophages and imaging 
plaque inflammation (Hyafil et al., 2007). Using a rabbit model of atherosclerosis 
involving double balloon injury combined with a high fat diet, N1177 was used for in 
vivo detection of macrophage containing lesions using a clinical CT scanner 2 hours 
following intravenous administration. CT images of macrophage density showed 
good correlation with histological staining (Hyafil et al., 2007). N1177 showed 
superior imaging of plaque density compared with a conventional CT tracer but the 
dose of iodinated N1177 employed was high and patient tolerability to a functional 
dose may well be a limiting factor. 
Theranostics 
The high atomic number of gold coupled with its low toxicity profile make it a more 
desirable CT imaging agent than iodine and more likely to gain regulatory approval 
than some of the more exotic metals beings trialed due to its long history of use in 
humans. A new avenue emerging in the nanoscience field is the design and 
synthesis of nanomaterials that offer a therapeutic and diagnostic option with 
photothermal therapy. The combination of NP design and laser excitation 
wavelength can induce absorption of light and subsequent conversion to heat. 
Following NP binding to or uptake by cells, the thermal energy from the NP is 
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transferred via convection to the surrounding cellular medium resulting in thermal cell 
death. Gold NPs can be shaped to allow absorption of heat from an external light 
source, creating an excellent inducer of the photothermal effect. CT can be utilized 
with NIR light sources to measure uptake of gold into cells and subsequent response 
to thermal destruction of tumor cells (von Maltzahn et al., 2009) and in macrophages 
within arterial lesions (Qin et al., 2015). As will be outlined in subsequent sections, 
photothermal therapy utilizing gold NPs is a strategy also being developed for other 
imaging/theranostic modalities. 
Advantages and barriers to translation 
The key advantages of CT include speed of imaging, the body-wide view and its 
established use within the clinic for anatomical and limited functional imaging. As 
one of the main imaging modalities, CT scans have quick clinical turnover and are 
well tolerated by a majority of patients. In fact, CT is widely used in the field of 
inflammation imaging as recently reported by the Antoniades group who 
demonstrated that changes in the lipid and water content of perivascular fat tissue 
surrounding human coronary arteries was a marker of the underlying vascular 
inflammation associated with atherosclerotic plaques and could be detected by CT in 
human patients (Antonopoulos et al., 2017; Oikonomou et al., 2018). This offers the 
potential of CT as an early diagnostic tool for indirectly measuring inflammation in 
the early stages of atherosclerosis. However, the low sensitivity (10-2-10-3 mol/L), 
radiation burden and a spatial resolution insufficient to discriminate inflammation 
‘hot-spots’ within the relatively large voxel areas (Sandfort et al., 2015) are likely to 
be insurmountable obstacles for clinical translation of CT as a true molecular 
imaging modality. 
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2.5 Magnetic Resonance Imaging (MRI)/Magnetic Particle Imaging (MPI) 
MRI is one of the most studied modalities for functional, anatomic and cellular 
imaging at a clinical level. Non-contrast MRI is readily used for acquiring anatomic 
information but if molecular imaging is needed, it requires the use of contrast agents 
owing to poor sensitivity, the main limitation of MRI. While sensitivi ty of MRI is 
superior to CT with ranges from ~10 µM to ~ 10 mM (Sinharay and Pagel, 2016), it is 
orders of magnitude lower than that obtained by nuclear or optical imaging systems 
(James and Gambhir et al., 2012) and this limits MRI to situations where contrast 
agents are highly accumulating through passive means or through binding to highly 
expressed biomarkers in targeted MRI (Table 1). 
There are four principal classes of contrast agents used for MRI and each differs in 
the mechanism of signal generation: 
1) T1 and T2/T2* contrast agents 
T1–weighted MRI consists of positive contrast agents, typically chelates of 
paramagnetic metal ions, usually gadolinium (Gd3+), with detection limits in the 
micromolar range. These are generally small molecule chelates with many approved 
for clinical use. Attempts to overcome the low sensitivity have involved encapsulation 
of Gd3+ into various NPs such as dendrimers, micelles or high-density lipoprotein 
(HDL) type NPs (Kircher and Willmann et al., 2012). These NPs can allow delivery of 
larger payloads of imaging agent, improving sensitivity while reducing the likelihood 
of release of the toxic free Gd3+ element. 
T2-weighted MRI occurs when negative contrast imaging agents are employed. The 
mainstay imaging agent for T2 MRI has been the super-paramagnetic iron oxide 
particles (SPIOs) owing to their high magnetization properties. These particles are 
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usually dextran coated and have evolved since their inception in the 1980s to smaller 
more refined coated particles (USPIOs), with a diameter 10-50 nm and these have 
been the primary focus to date in moving MRI towards a tool more amenable for 
molecular imaging. There also exists larger iron oxide-based contrast agents called 
micron-sized iron oxide particles (MPIOs) that are typically greater than 1 µM in 
diameter. As will be outlined below, however, even those agents to gain regulatory 
approval have struggled to maintain a foothold in the imaging market. 
2) Fluorinated contrast agents 
The 19F nucleus has properties that offer MRI signal intensities approaching that of 
hydrogen protons (Ruiz-Cabello et al., 2011) yet is present in only trace amounts in 
the soft tissues of the human body, thus is a suitable choice for an exogenous 
contrast agent when high signal to noise ratio is required. 19F contrast agents have 
centered on perfluorocarbons (PFCs) where the hydrogen atoms are replaced by 19F 
atoms and which can subsequently be concentrated/encapsulated by a lipid bilayer 
at near nanoscale size delivery vehicles, allowing targeting to molecular markers or 
drug conjugation for therapeutic delivery. The key advantage of 19F MRI is that the 
signal directly correlates to the binding/uptake of 19F at the site of interest, allowing 
quantification of the target. Being detectable by classical MRI (if a 19F-tuned RF coil 
is equipped), 19F MRI still requires >10-5 M of 19F in the tissue for detection at 1.5-T 
(Ruiz-Cabello et al., 2011; Terreno and Aime, 2015). 
3) Chemical exchange saturation transfer (CEST)/paraCEST 
CEST and paraCEST compounds utilize a different form of magnetic imaging, 
namely reducing the magnetization of the water signal with limited effects on the 
relaxation rate. The process involves part of the CEST agent undergoing magnetic 
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resonance by application of a radiofrequency pulse which promotes saturation of the 
proton and chemical exchange with water molecules in which the saturated proton is 
transferred to the water, resulting in saturation of a proton within the water molecule. 
The remaining unsaturated water molecules can be used to provide an MRI signal 
(Sinharay and Pagel, 2016). The limitation of this technique is the slow exchange 
between molecules resulting in poor sensitivity and the requirement for large 
concentrations (mM range) of target molecules. ParaCEST exclusively employs 
exogenous paramagnetic agents capable of exchanging protons or water molecules 
with endogenous tissues. These may include NPs conjugated to paramagnetic ions, 
thus exposing them to water protons. By tuning the magnetic resonance frequency to 
the exchangeable saturated protons, contrast signals can be differentiated from the 
surrounding bulk water. ParaCEST agents offer faster proton exchange and 
therefore are a more sensitive adaptation of traditional CEST (Viswanathan et al., 
2010). 
4) Hyperpolarized MRI 
Hyperpolarized MRI was/is being developed to overcome the poor sensitivity of 
traditional MRI. Developed in the early part of this century, with first human trials in 
2010, it is fast gaining momentum, owing to its potential exponential gains in imaging 
resolution. The abundance of water in human tissues means only a small fraction of 
protons in water molecules require magnetic alignment for a signal to be obtained. 
Thus, MRI has been developed around detection of hydrogen protons. The detection 
of other nuclei that may be incorporated into an imaging agent such as 13C or 19F 
would be present at concentrations orders of magnitude lower than 1H and would not 
be resolved via traditional MRI but can be resolved by hyperpolarized MRI by 
increasing the % of atomic nuclei in alignment (Golman et al., 2003). Several 
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methods exist for creating hyperpolarized MRI agents but dynamic nuclear 
polarization (DNP) is the most common and can boost signal intensity by 10,000 
times (Ardenkjaer-Larsen et al., 2003) compared with traditional MRI methods. 
Magnetic Resonance Spectroscopy (MRS) is a complimentary tool to MRI, used for 
detecting primarily 1H atoms within certain metabolites present within a single voxel 
of interest. To detect a 1H signal within molecules present at such a low abundance 
with respect to water and fat, it is necessary to separate (or suppress) the water 
signal during MRS acquisition.The acquisition of molecular spectra by MRS can be 
used to determine metabolic changes that may reflect pathological processes. Since 
the signals from the molecules of interest in MRS are present at relatively low 
concentrations, suitable field strengths are required for clinical MRS, with 3-T 
scanners offering higher sensitivity and the ability to obtain spectra from smaller 
voxels (Van der Graaf, 2010). The particular method of MRS employed depends on 
what information is required. Typically, MRS uses single voxel spectroscopy (SVS) 
for a particular localized region of interest. Imaging of several voxels can be used for 
mapping spatial distribution of a metabolite of interest (e.g across a tumor) and 
utilizes magnetic resonance spectroscopic imaging (MRSI) but at the expense of 
quantification accuracy (Faghihi et al., 2017). MRS can identify various molecules 
within tissue, dependent on concentration and magnetic field strength. These include 
creatine, choline, N-acetyl aspartate (NAA), alanine, lactate, taurine, glycine, myo-
inositol, intracellular lipids and glucose (Verma et al., 2016). Of these, NAA, creatine 
and choline are the most widely utilised and historically, MRS has been a tool 
applied for studying disorders of the brain. 
Magnetic Particle Imaging (MPI) is a recent technological development (Gleich et al., 
2005) that directly detects magnetic NPs (almost exclusively iron oxide NPs thus far) 
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and produces positive contrast from the tracer directly (a list of MPI tracers can be 
found in Panagiotopoulos et al., 2015). MPI offers superior sensitivity and potential 
gains in spatial resolution over conventional MRI as well as fast imaging times 
(Gleich et al., 2005; Saritas et al., 2013). The basis for these improvements is that 
the signal (i.e. NP derived) is not present in the body naturally thus offering superior 
contrast and sensitivity over traditional MRI. 
Clinical use 
As stated above, MRI is an excellent tool for imaging the soft tissue components 
within the human body, offering a safer form of imaging, free of ionizing radiation. 
MRI can form part of the diagnostic work up for investigating abnormalities within the 
cardiovascular, musculoskeletal, gastrointestinal and other tissues, providing both 
anatomic and in some circumstances, functional imaging, such as perfusion imaging. 
The majority of contrast enhanced MRI utilizes T1 based approaches. However, over 
the history of MRI, a number of iron oxide-based imaging agents have been 
approved for clinical use, particularly dextran coated NPs, due to low toxicity and 
straightforward manufacturing (Mulder et al., 2014). Despite a relatively good safety 
profile (side effects are likely a result of coating material rather than iron oxide per 
se), use of SPIONs has failed to meet initial expectations and only a select number 
of agents are still on the market due to poor clinical uptake and low 
sensitivity/specificity for intended purpose (Smith and Gambhir, 2017). 
MRS is a clinically useful tool for studying a range of diseases including brain 
tumors, Alzheimer’s disease and seizures. MRS has also been applied to 
neuroinflammatory diseases, most notably MS. While inflammatory molecules are 
not directlty detected, metabolite levels can inform on the severity and clinical stage 
of the disease, as reviewed in detail by Chang et al. (2013). 
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Pre-clinical use and in-human trials 
Human studies using contrast MRI in the context of measuring inflammation are 
limited and all have utilized passive uptake of USPIOs/SPIOs by macrophages. 
Since these studies depend on T2* contrast changes of iron concentrations within 
the tissue, either as a result of the EPR effect and/or macrophage uptake, they don’t 
meet the criteria of true molecular imaging. Despite this, the use of SPIONs appears 
an attractive option for imaging inflammation, particularly in disease states such as 
atherosclerosis, RA and IBD, where macrophages are a key component of the 
involved pathologic lesion, allowing either passive uptake via phagocytosis or active 
targeting to macrophage surface receptors. Readers are referred to reviews by Jin et 
al. (2014) and Neuwelt et al. (2015) which cover the use of SPIO passive imaging by 
MRI. To our knowledge, there are no in-human trials currently taking place in the 
context of inflammation that utilse the other forms of MRI described above. Although 
several trials involving 19F-MRI are underway, particularly in relation of cystic fibrosis, 
the focus of these trials is not on the inflammatory components of the disease. CEST 
agents based around glucose detection are in early clinical trials for oncology but as 
of yet, are not designed for measuring inflammation. 
There are, of course, a multitude of studies in animal models, utilizing passive 
SPIOs/USPIOs and 19F-PFCs to quantify inflammation via macrophage uptake, 
particularly in the context of atherosclerosis but what follows will only be a review of 
key pre-clinical work that employ active molecular targeting of MRI compatible 
imaging agents to keep within the remit of our discussion. Direct targeting of SPIOs 
via modifications with ligands such as antibodies, aptamers and peptides allows MRI 
to be used to monitor SPIO binding/uptake at the site of disease, improving signal to 
noise and diagnostic capability. Key molecules of interest in this area of research 
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have been adhesion molecules including the selectins (P- and E-selectin), vascular 
cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), 
all of which are upregulated on endothelial cells in inflammatory conditions such as 
atherosclerosis, MS and stroke and are some of the earliest biomarkers signifying 
cellular inflammation/activation, even before other pathological signs are evident. A 
summary of targeted MRI studies can be found in Table 1. 19F-PFCs containing 
chelated gadolinium targeted to fibrin were first validated by Morawski et al. (2004) in 
human carotid endarterectomy samples (areas of atherosclerotic plaque) at 4.7-T 
allowing detection of the thrombus via the targeted localized 19F signal and 
associated anatomical details via the T1 signal from gadolinium. Furthermore, the 
19F signal was intense enough to allow spectroscopic quantification of the bound 19F, 
a proof of concept that demonstrated that multiple configurations of 19F-PFCs, each 
with distinct spectroscopic profiles, could be used to target multiple biomarkers 
(Morawski et al., 2004). CEST has found research use in detecting enzyme activity, 
metabolic function (e.g. glucose utilization), hypoxia, neurotransmitter (glutamate) 
levels, ion concentration and pH (Sinharay and Pagel, 2016). The large 
concentrations required of either endogenous or exogenous CEST compatible 
agents would seemingly limit its usefulness in imaging inflammation. Despite this 
limitation, glutamate, which is amenable to CEST MRI is elevated in inflammatory 
brain disorders such as MS and amyotrophic lateral sclerosis (ALD). Results have 
shown that CEST MRI brain images of glutamate (Glu-CEST) distribution align with 
PET images (Cai et al., 2012a) at 7-T, showing the potential for CEST to indirectly 
measure inflammation in neurological disease. Moreover, in animal models of 
Alzheimer’s disease, Glu-CEST can differentiate diseased areas from non-diseased 
areas (Haris et al., 2013). GAGs in cartilage are also detectable by CEST imaging 
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allowing the tracking of joint cartilage changes in human subjects (Ling et al., 2008; 
Schmitt et al., 2011). ParaCEST imaging agents have been combined with 19F-PFCs 
to offer improved sensitivity and quantifiable targeting of NPs. The use of NP sized 
formulations has greatly increased the potential of paraCEST, specifically the 
development of lanthanide containing liposomes (lipoCEST) designed to improve the 
sensitivity of the system down to the nM level (Flament et al., 2013). A key 
advantage of CEST based MRI is the ability to image two or more imaging tracers in 
one scan (duplexing), provided the CEST agents display good sensitivity and have 
sufficiently different resonance frequencies of their mobile protons (Castelli et al., 
2013). This has been demonstrated to be feasible for lipoCEST agents in a proof of 
concept study using local injection of non-targeted contrast agents into the thigh 
muscle of a mouse with clear discrimination of the two contrast agents visible on the 
scans (Terreno et al., 2008). LipoCEST agents have also been functionalized with 
targeting ligands. This was first attempted by Flament et al. (2013) using αvβ3 
(integrin present on new forming blood vessels) targeted lipoCEST NPs in a mouse 
tumor model and although some non-specific binding was observed, it is a starting 
point towards developing more refined lipoCEST agents which would be desirable 
given their higher level sensitivity along with the inherent multiplexing capacity of 
CEST. 
The major use of hyperpolarized MRI has been to use 13C- containing compounds 
such as pyruvate for imaging metabolic pathways as the 13C is passed down through 
metabolites allowing fast imaging of the metabolic state of the target tissue. 
Recently, the use of [1-13C] pyruvate imaging in the heart has shown promise for the 
detection of cardiac inflammation. Lewis et al. (2018) discovered that the metabolism 
of [1-13C] pyruvate to [1-13C] lactate in infarcted murine and porcine hearts was the 
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result of an increased rate of glycolysis in activated monocytes/macrophages, which 
was linked to IL-1β release. Thus, hyperpolarized MRI may offer a novel method for 
imaging inflammation following myocardial infarction (Lewis et al., 2018). 13C-
pyruvate has also been researched to detect inflammation through increased 
metabolism in animal models of arthritis (MacKenzie et al., 2011) and MS 
(Guglielmetti et al., 2017). 
In addition to MS, significant data exists in human studies to demonstrate that MRS 
can detect metabolic changes indicative of Alzheimer’s disease and precursor 
conditions such as mild cognitive impairment. As the major detectable metabolite in 
neurons, low NAA can be associated with loss of neuron viability/density while 
conversely, elevated myo-inositol is a biomarker of glial cell activation/proliferation 
and these two changes have repeatedly been demonstrated in the brains of 
Alzheimer’s patients (Zhu et al., 2006; Rami et al., 2007). Reduced choline 
concentration, as an adjunct to NAA and myo-inositol analysis, may also increase 
sensitivity to brain changes associated with cognitive decline (Tumati et al., 2013). 
Theranostics 
MRI has many features that make it a useful theranostic tool such as good spatial 
resolution, body wide imaging and a diverse group of combinable carriers and 
contrast agents that can be adapted to each theranostic application. A recent 
promising example of iron oxide targeted theranostic NPs was in the context of acute 
graft rejection. Guo and colleagues utilized CD3 (T cell specific receptor) targeted 
iron oxide NPs that also contained a therapeutic gene. Both in vitro and in vivo, using 
a rat heart transplant approach, the authors successfully delivered the gene to T 
cells, thus reducing the T cell mediated destruction of the transplanted heart with 
MRI being utilized to monitor the T cell accumulation via the uptaken iron oxide NPs. 
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The effect was shown to be specific to CD3 targeted gene carrying NPs, results 
confirmed by NIRF imaging (Guo et al., 2012). In the work by Myerson et al., 2011, 
PFCs targeted to thrombin via an anti-thrombin agent was a novel development 
whereby the thrombin inhibitor, PPACK, irreversibly binds to thrombin on the clot 
surface, thus inhibiting thrombin activity (Myerson et al., 2011). Given the low toxicity 
of PFCs in humans (Palekar et al., 2015), it is conceivable that targeted PFCs 
containing 19F substituted atoms and/or Gd3+ chelates could be a viable non-invasive 
tool for delivering and monitoring efficacy of anti-inflammatory drugs targeted to 
disease specific molecules that show relatively high abundance such as fibrin. CEST 
and paraCEST agents are being developed and tested pre-clinically using drug 
loaded liposomes, to track and monitor drug delivery, mostly in the field of oncology 
(Castelli et al., 2014). Proof of concept for monitoring the delivery of anti -
inflammatories or modulating inflammatory conditions is lacking. 
Advantages and barriers to clinical translation 
Iron oxide-based agents, having already been approved for human use, have one 
less barrier to novel uses for in-human imaging. Rather disappointingly, however, 
several previous iron oxide-based imaging agents have been discontinued due to 
poor performance or safety issues, with only Ferucarbotran (Resovist®) retaining 
use as an MRI contrast agent in a few countries. This leads to a requirement for new 
agents to be developed if T2 MRI molecular imaging is to be adopted more broadly 
in a clinical setting. Technical issues associated with USPIO molecular imaging that 
require to be overcome include low signal to noise ratio, poor specificity associated 
with ability to clearly discriminate signal between tissue locations, long imaging times 
and the challenge of standardizing conditions between scans due to patient position 
and magnetic field discrepancies (Schmitz et al., 2000; Ruehm et al., 2001; Sadat et 
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al., 2014). PFCs, which dominate the pre-clinical and early phase 19F human trials 
are strong candidates for regulatory approval due to relatively good biocompatibility, 
biodistribution and favorable toxicity compared with other contrast agents in clinical 
use. Indeed, PFCs may be safer for human use than metal-based contrast agents 
(Palekar et al., 2015). Future studies will need to determine if localized 19F is 
detectable in human patients at a tolerable administered dose of 19F-PFC NPs. 
These prospects will be improved by wider clinical adoption of 7-T MRI which allows 
higher sensitivity detection of 19F (Schmieder et al., 2015). CEST agents can be 
utilized in NP formulations to boost sensitivity although most of these studies have 
only been at the in vitro level. In vivo comparisons of lipoCEST agents with T1 and 
T2 based liposomes have shown that the CEST signal is more transient due to 
accumulation in subcellular compartments of macrophages which suppresses the 
CEST signal. Hyperpolarized MRI was designed to overcome the limitations of 1H or 
19F based MRI with profound increases in sensitivity possible. At present, only a few 
molecules incorporating hyperpolarized nuclei such as 13C have been tested in vivo 
and have focused on metabolic molecules as markers of tumor progression or 
inflammation (not dissimilar to the use of 18F-FDG in PET imaging). The main 
limitation of hyperpolarized MRI to date has been the transient nature of the 
hyperpolarized state, making practical use of the technology problematic. Despite 
this, proof of concept studies have shown that NPs composed of a hyperpolarized 
29Si nuclei can be imaged for over 40 minutes following injection in mice and with low 
toxicity (Cassidy et al., 2013), indicating the potential for future advances towards 
wider imaging applications. 
MPI is a new technology only developed in 2005, thus current deployments center 
around limited numbers of small pre-clinical scanners designed for rodent sized 
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imaging (Saritas et al., 2013; Panagiotopoulos et al., 2015). The current state of MPI 
remains as ‘a promising technology’ that can take the best aspects of MRI and 
improve on this with better sensitivity, higher temporal resolution and easier 
interpretation of scans due to the signal intensity correlating with the iron oxide 
loaded NPs, without any background signal. Since MPI produces no anatomical 
detail, it will likely be combined with other modalities with combined MPI/MRI 
imaging already tested for imaging the heart and vasculature (Kaul et al., 2015). 
Clinical concentrations of Resovist have shown to be suitable for in vivo MPI imaging 
(Weizenecker et al., 2009) and the development of new SPIONs tailored to MPI use 
should greatly increase performance and facilitate the clinical testing of MPI as a 
highly sensitive, fast, quantitative vascular, cellular and potentially molecular imaging 
tool (Vaalma et al., 2017). 
 
 
Table 1. Key examples of inflammatory biomarkers targeted by MRI 
Target Tracer(s) FDA/CE 
approved 
(commerci
ally 
available) 
Disease(s) and 
study type 
Comments Reference(s) 
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VCAM-1 VINP-28 
(VCAM-1 
targeted NP) 
 
P03011 
(VCAM-1 
targeted 
USPIO) 
No (No) 
 
 
 
No (No) 
Atherosclerosis 
(pre-clinical) 
 
 
Atherosclerosis 
(pre-clinical) 
9.4-T imaging in apoE-
/- mice 
 
 
Imaging of both early 
and late stage 
pathology in apoE-/- 
mice using 17.6-T MRI 
Nahrendorf et 
al., 2006 
 
 
Michalska et 
al., 2012 
VCAM-1/P-
selectin 
Dual-targeted 
MPIOs 
No (No) Atherosclerosis 
(pre-clinical) 
Dual-targeted MPIOs 
showed superior 
binding and MRI signal 
in apoE
-/-
 mice 
compared with single 
targeted particles 
McAteer et al., 
2008 
E-/P-selectin Targeted 
glyconanopart
icles 
No (No) EAE (MS 
model) 
(pre-clinical) 
Early inflammation 
(pre- clinical 
symptoms) was 
detectable without loss 
of blood-brain barrier 
integrity 
van Kasteren et 
al., 2009 
ICAM-1 Targeted 
MPIOs 
 
 
 
 
 
 
No (No) 
 
 
 
 
 
 
 
Mouse stroke 
model 
(pre-clinical) 
 
 
 
 
 
Early inflammation 
post-stroke was readily 
visualized in vivo with 
ICAM-1 targeted 
MPIOs but not ICAM-1 
targeted Gd liposomes. 
This data supports 
other studies that 
Deddens et al., 
2013 
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Targeted 
MPIOs 
 
 
 
 
No (No) 
 
 
 
 
EAE 
(pre-clinical) 
MPIOs are superior 
contrast agents in vivo 
 
Blood vessel 
inflammation in the 
brain was detected by 
MRI in EAE mice 
without loss of blood-
brain barrier integrity 
 
 
 
 
Blezer et al., 
2015 
Complement 
receptor type 
2 (CR2) 
SPIO NP No (No) Renal 
inflammation in 
mice (nephritis) 
(pre-clinical) 
Targeted but not 
passive SPIOs were 
able to visualize 
inflammation in 
different kidney 
compartments in mice 
with nephritis 
Serkova et al., 
2010 
Fibrin EP-2104R 
(Gd based 
targeted 
contrast 
agent) 
No (No) Coronary 
thrombosis in 
swine 
(pre-clinical) 
MRI imaging could 
assess location and 
size of thrombus within 
the coronary arteries of 
pigs using a clot 
targeted Gd based 
agent 
Botnar et al., 
2004 
glycoprotein 
αIIbβ3 
P975 (Gd 
based 
targeted 
contrast 
agent) 
No (No) Carotid 
thrombosis in a 
mouse model 
(pre-clinical) 
MRI signal in 
thrombotic vessels but 
not in healthy 
contralateral carotid. 
Administration of an 
Klink et al., 
2010 
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αIIbβ3 antagonist 
resulted in signal loss 
indicating target 
specific imaging 
MMPs P947 (Gd 
based 
targeted 
contrast 
agent) 
No (No) Atherosclerosis 
(pre-clinical) 
MRI imaging revealed 
contrast signal was 3x 
higher in 
atherosclerotic vessels 
than control. Contrast 
agent was also rapidly 
cleared from the 
circulation (~95% 
within 1 hour) allowing 
minimal background 
noise 
Lancelot et al., 
2008 
Fibrin 
19
F-PFC Gd 
containing 
NPs 
 
 
 
 
 
 
 
 
 
19
F-PFC-
paraCEST 
No (No) 
 
 
 
 
 
 
 
 
 
 
 
No (No) 
Atherosclerosis 
(pre-clinical) 
 
 
 
 
 
 
 
 
 
 
Thrombosis (in 
vitro blood clots) 
A 
19
F combined with 
Gd T1 based NP 
targeted to fibrin was 
tested on isolated 
human arterial plaques 
at 4.7-T and revealed 
specific binding to clot 
surface at a minimum 
NP concentration of 1 
nM at the clot. 
 
Dual paraCEST and 
19
F imaging of a clot 
using fibrin targeted 
Morawski et al., 
2004 
 
 
 
 
 
 
 
 
 
 
Cai et al., 
2012b 
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contrast NPs  NPs allowed MRI 
imaging by either 
19
F or 
paraCEST at NP 
concentrations below 5 
nM 
 
VCAM-1 
19
F-PFC NPs 
 
 
 
 
 
 
19
F-PFC NPs 
No (No) 
 
 
 
 
 
 
No (No) 
Atherosclerosis 
(pre-clinical) 
 
 
 
 
 
Atherosclerosis 
(pre-clinical) 
 MRI revealed 
inflammation in plaque 
burdened renal arteries 
via 
19
F signal via 
VCAM-1 bound NPs 
 
ApoE
-/-
 mice were 
injected with VCAM-1 
targeted 
19
F-PFC NPs 
and aortas removed for 
ex vivo MRI analysis 
revealing specific 
binding to arterial 
areas with lesion 
formation 
Southworth et 
al., 2009 
 
 
 
 
 
Pan et al., 2013 
Thrombin 
19
F-PFC NPs No (No) Arterial 
thrombotic 
injury 
(pre-clinical) 
Following surgical 
induction of arterial 
injury, mice were 
administered thrombin 
targeted 
19
F-PFC NPs 
and vessels excised 
and assessed at 11.4-
T MRI revealing highly 
Myerson et al., 
2011 
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localized accumulation 
of NPs at clot locations 
αvβ3 lipoCEST 
targeted NP 
No (No) Angiogenesis αvβ3 targeted NPs were 
in vivo imaged in new 
blood vessels within 
brain tumors of mice 
using 7-T MRI. 
Histology revealed NPs 
were bound to αvβ3 
expressing cells 
Flament et al., 
2013 
Caspase-1 
19
F-
nanoprobe 
No (No) Induced local 
inflammation 
Caspase-1 is involved 
in the release of pro-
inflammatory cytokines 
and in this study was 
targeted using an 
activatable 
19
F-
nanoprobe, yielding a 
19
F signal which 
correlates with 
Caspase-1 activity. 
Akazawa et al., 
2018 
Elastin  Gd based 
elastin probe 
+ USPIO 
No (Yes) Abdominal 
aortic aneurysm 
(AAA) 
The combined 
assessment of 
extracellular matrix 
degradation and 
inflammatory cell 
activity was used in a 
mouse model of AAA 
to predict the risk of 
Brangsch et al., 
2019 
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2.6 Nuclear Imaging (PET/SPECT) 
Like CT and MRI, nuclear imaging offers the ability to image the entire dimensions of 
the human body. Together, PET and SPECT form the cornerstone of nuclear 
imaging. PET/SPECT are attractive options for molecular imaging owing to their non-
invasive nature and high sensitivity (10-10-10-11 M for SPECT and (10-11-10-12 M for 
PET) (Stendahl and Sinusas, 2015). High levels of sensitivity allow reductions in the 
dosage of contrast agents, which is critical when the contrast agent is radioactive or 
otherwise toxic. At the center of clinical PET imaging is 18F-FDG, a glucose analogue 
that is metabolized by metabolically active cells. Tumor cells are highly metabolically 
aneurysmal rupture 
α4β1 THI0567-
targeted 
liposomal-Gd 
No (No) Atherosclerosis 
(pre-clinical) 
Using a 1-T small 
animal scanner, 
atherosclerotic lesions 
in apoE-/- mice were 
detected via binding of 
the tracer to sub-
endothelial 
macrophages within 
the plaque. Signal was 
specific to targeted 
particles and may offer 
a non-invasive meaure 
of plaque inflammatory 
activity with higher 
signal to noise 
compared with PET. 
Woodside et 
al., 2018 
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active. They undergo rapid rates of division which increases demand for glucose in 
addition to actively inducing angiogenesis. Increased glycolysis is also a feature of 
the immune system following activation. This is most evident for those immune cells 
that can participate in phagocytosis such as macrophages and neutrophils. 
Therefore, 18F-FDG can be used to identify areas of macrophage 
activation/accumulation. 18F-FDG sits at the boundary of molecular and metabolic 
imaging, offering high sensitivity detection (although this is frequently associated with 
poor signal to noise due to non-specific uptake by healthy cells, particularly 
cardiomyocytes). PET has also seen numerous radiolabeled small molecules being 
developed that can be targeted to various inflammatory molecules (Figure 1) to 
provide more information on the tissue state than simple energy use. Since 
PET/SPECT lack anatomical details, to enhance localization and improve diagnostic 
sensitivity, nuclear medicine modalities are commonly combined with CT in hybrid 
imaging systems which can provide high resolution anatomic details to be 
superimposed on the PET/SPECT image. PET/SPECT can also be combined with 
MRI for similar purposes due to the high soft tissue contrast obtained by MRI. 
Clinical use 
18F-FDG is routinely used in the clinic within the field of oncology, both to locate the 
presence of tumors, disease staging and to assess shrinkage of tumors in response 
to treatment; however, 18F-FDG-PET is also increasingly being used for non-
oncological purposes in fields covering CVD (Pelletier-Galarneau and Ruddy, 2019), 
neurology, infection and inflammatory disorders (Zhuang and Codreanu, 2015). 
Here, we will only summarize clinical use pertaining to inflammatory diseases. 18F-
FDG PET is used for monitoring disease in cardiac sarcoidosis patients 
(Glaudemans et al., 2013). 18F-FDG PET is useful where MRI may be 
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contraindicated due to implanted cardiac devices. A further advantage of PET in this 
context is more accurate diagnosis and the identification of disease in extra-cardiac 
sites such as the liver, bone and spleen (Patel et al., 2017) which may be missed by 
MRI due to a narrow view window. Identifying the disease in other organs other than 
the heart will allow more accurate staging and to initiate treatment accordingly. Other 
inflammatory conditions including vasculitis are also imaged in the clinic; this is an 
increasingly common use of PET but requires the operator to be trained in the 
specific protocols related to this particular pathology (Hautzel et al., 2008). Due to 
the poor spatial resolution of PET, imaging of vasculitis is restricted to large caliber 
arteries such as the aorta but imaging of smaller arteries (usually 1st order aortic 
branches) is possible if the camera has sufficient resolution (=<2.5mm) allowing 
differentiation of inflammatory vascular conditions such as giant cell arteritis (GCA), 
Takayasu’s arteritis (TA), and polyarteritis nodosa (PAN) (Glaudemans et al., 2013). 
Although some encouraging results have emerged from studies using a small 
number of patients, there is currently insufficient evidence to justify the routine 
clinical use of 18F-FDG in RA, pancreatitis, IBD, tuberculosis and osteomyelitis. In 
2013, combined guidelines from the European Association of Nuclear Medicine 
(EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) were 
published for the use of FDG-PET in inflammation and infection, outlining the clinical 
evidence (or lack off) for the justification of 18F-FDG in imaging inflammation (Jamar 
et al., 2013). Readers can refer to this document for a more detailed account of the 
many issues and criteria that must be addressed/overcome for 18F-FDG to be 
recommended as a tool to improve clinical diagnosis. It is also worth noting how few 
the inflammatory disease states are that the EANM and SNMMI consider having 
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sufficient evidence to warrant clinical 18F-FDG imaging. For now, at least, 18F-FDG-
PET in the clinic is still primarily a tool for oncologists. 
Pre-clinical use and in-human trials 
Although 18F-FDG is employed as a diagnostic tool in inflammatory vasculitis 
conditions, it is not employed clinically to diagnose atherosclerosis, heart attack or 
stroke. This is despite atherosclerotic plaques being inadvertently detected in 
patients undergoing scans for cancer and a number of studies indicating potential 
clinical value as will now be outlined. A widespread assessment of the likelihood of a 
person developing CVD is called the Framingham risk score (FRS), originally 
introduced in 1998 and updated in 2008. Interestingly, an assessment of 1,181 
asymptomatic subjects administered 18F-FDG to measure carotid plaque uptake via 
PET indicated that persons with elevated plaque uptake of 18F-FDG had an 
increased chance of an elevated FRS of 10% or more (Odds ratio: 1.9) (Noh et al., 
2013). Retrospective studies using 18F-FDG have also demonstrated that this 
method independently predicts CVD risk, even beyond that predicted by FRS 
(Figueroa et al., 2013). Furthermore, 18F-FDG PET/CT has been employed in human 
patients to detect symptomatic carotid atherosclerosis (Rudd et al., 2002). One final 
example where 18F-FDG-PET can have predictive power in CVD is in predicting 
recurrent stroke. 18F-FDG-PET imaging of carotid artery inflammation in prior stroke 
patients predicts the recurrence of cerebrovascular stroke, independent of other 
factors (Marnane et al., 2012). These studies and others highlight the potential of 
18F-FDG-PET as a stand-alone tool for assessing atherosclerosis associated 
inflammation and plaque severity and can yield good signal to noise ratios with little 
background from healthy arterial walls. This raises hope that by targeting glucose 
metabolism as an indirect measure of inflammation, PET could also act in co-
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ordination with classical arterial angiograph methods to guide surgical and 
pharmacological intervention. There are several co-morbidities that act to increase 
the risk of developing CVD. One such disease is psoriasis (Prodanovich et al., 2009; 
Brauchli et al., 2009). Using 18F-FDG-PET, Naik et al., 2015 demonstrated that 
psoriasis patients with no history of CVD had increased aortic 18F-FDG uptake which 
increased proportionally with the severity of psoriasis. Therefore, 18F-FDG-PET could 
be an early diagnostic tool in psoriasis patients for detecting the vascular 
inflammatory changes that may signify the onset/progression of atherosclerosis. A 
similar increase in vascular inflammation has also been observed in RA patients, a 
disease associated with ~50% enhanced CVD risk (Rose et al., 2013). 
Several studies have employed 18F-FDG-PET to measure response to anti-
inflammatory therapies. To date, there are five classes of drugs used to treat CVD 
where both clinical endpoint and PET imaging are available. Clinical trial endpoints 
have shown positive for two classes of treatments (statins and thiazolidinediones) 
which correlated with 18F-FDG-PET findings of vascular inflammation (Osborn et al., 
2017). Ability to measure specific pathogenetically related outcomes rather than 
awaiting clinically significant CVD events improves time and cost of trials as well as 
patient safety in case of ineffective treatments. Therefore, 18F-FDG-PET can be used 
to not only detect inflammation in the primary disease but to assess cross-disease 
risk, monitor disease progression and even monitor response to therapy. 
The use of radiolabeled metabolic precursors is not limited to 18F-FDG. Choline, a 
molecule involved in the synthesis of cell membranes is taken up by rapidly 
proliferating cells (such as macrophages during inflammation) and has been utilized 
for PET as either 18F-choline or 11C-choline. A feasibility study in humans showed 
the potential of imaging vascular changes associated with CVD using 18F-choline 
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(Bucerious et al., 2008) and this molecule is currently undergoing further evaluation 
in human trials (ClinicalTrials.gov identifiers: NCT01899014 and NCT02640313). 
While Technetium-99m (99mTC) and 18F-FDG remain central to current nuclear 
imaging, pre-clinically, a multitude of novel targeted radiolabeled tracers have been 
developed, many of which target inflammatory molecules (Figure 1). Table 2 
provides a summary of the most important pre-clinical studies utilizing PET and 
SPECT imaging agents targeted to inflammatory biomolecules. Although, both the 
clinical and pre-clinical nuclear imaging landscape is dominated by small molecule 
tracers, NPs conjugated to or containing a core of radiolabeled tracers have been 
developed. 99mTc radiolabeled NPs are commonly used in SPECT imaging and 
usually consist of Sulphur colloids ranging from 10-1000nm in diameter. Indeed, with 
the exception of iron oxide-based NPs used in MRI, 99mTc labeled colloid NPs remain 
the only clinically approved NPs for diagnostic imaging (Thakor et al., 2016). Gold 
NPs conjugated with ICAM-1 targeted antibodies show enhanced gamma ray 
production in the joints of arthritic rats (Shao et al., 2011). Since ICAM-1 is an early 
indicator of inflammation in arthritis, this is a key target of interest that could aid early 
diagnosis in RA in addition to other chronic inflammatory conditions. The first in 
human testing of a targeted radiolabeled NP has taken place in melanoma patients 
(Phillips et al., 2014; ClinicalTrials.gov: Identifier: NCT01266096). A more relevant 
development has been the first receptor-targeted NP agent for cardiovascular 
imaging approved for clinical trials. The imaging agent (64Cu-25%-CANF-Comb), a 
16 nm copolymer based NP that targets natriuretic peptide receptor C (NPRC)- 
which is upregulated on atherosclerotic plaques- and has completed an early phase 
0 biodistribution and safety trial (ClinicalTrials.gov: Identifier: NCT02498379) with a 
phase 1 trial now ongoing to demonstrate the use of this NP PET agent for 
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identifying atherosclerotic plaques in the carotid arteries via PET/MR 
(ClinicalTrials.gov: Identifier: NCT02417688). Alternatively, targeted NP based 
approaches in atherosclerosis are being developed in animal models with CCR5 
(chemokine receptor upregulated on atherosclerotic plaques that facilitates immune 
cell entry into the vessel wall) targeted NPs showing promise in imaging disease in 
apoE-/- mice (Luehmann et al., 2014). 
Theranostics 
Direct use of radiolabeled tracers as therapeutic agents in themselves has focused 
on harnessing the radiolabel to induce cell death in the context of cancer. This 
involves exchanging the diagnostic gamma or positron emitting radiolabel with a beta 
emitter. To date, this process has mainly focused on targeting somatostatin 
receptors (SSTRs) on neuroendocrine tumors where peptide binding to the tumor 
cells induces internalization of the ligand/radiolabel and accumulation of the beta-
emitting isotope, leading to destruction of the tumor cells (Van Essen et al., 2009). 
Alpha emitting isotopes incorporated into tumor-targeted antibodies have also been 
tested clinically for a variety of cancers due to their highly destructive localized 
effects (Dekempeneer et al., 2016). Such approaches are unlikely to achieve such a 
disease specific cell/inflammatory target that would cause a beneficial therapeutic 
outcome without negative systemic effects on the immune system as a whole, since 
disease-specific cells/molecules would not be sufficiently localized for a targeted 
killing. 
Advantages and barriers to clinical translation 
PET has revolutionized the ability to non-invasively detect malignancies in the body. 
Great strides have been taken in terms of hardware and data processing to lower 
Jo
urn
al 
Pr
e-p
roo
f
Journal Pre-proof
  42 
radiation dose, improve resolution and combine the major strength of PET (high 
sensitivity) with the anatomic resolution available from MRI and in particular CT. 
Despite these advancements, the development pace of PET in terms of expanding 
beyond 18F-FDG and oncology has been slow. Over 95% of all clinical PET scans 
are 18F-FDG scans (Goel et al., 2017) and the vast majority are for oncology. 
Chemistry is not the bottleneck in PET tracer development with a variety of small 
ligands being radiolabeled and tested to varying degrees in the pre-clinical setting. 
Indeed, an inspection of the clinical trials database reveals that between 2005 and 
2015, there were actually more oncology trials using non 18F-FDG tracers (n=288) 
than using 18F-FDG (n=231). The non 18F-FDG trials tended to be registered later 
(2010-2015), be phase 0-2 and involve a smaller number of participants (Chen et al., 
2017). This indicates the rapidly expanding area of targeted PET imaging. As 
outlined above, 18F-FDG-PET imaging has proof of concept in detecting inflammation 
in CVD patients, to aid prognostic decision making and even to evaluate novel 
therapies. An important limitation of 18F-FDG-PET, however, is its poor performance 
in reliably detecting 18F-FDG in coronary arteries, blockages of which are the 
principal cause of heart attacks. Creation of accurate cardiac images also suffers 
from motion artifacts and partial-volume effects (Petibon et al., 2017). Moreover, 18F-
FDG-PET is only a gross readout of inflammation, focused on a single parameter, 
namely energy use, providing no information on the phenotype of the cells from 
which the increased FDG use is derived from. 
For targeted PET beyond FDG, several considerations need attention. The first is the 
suitability of the tracer. It should possess high potency and specificity to the 
biomarker of interest to provide good signal to noise and minimize radiation 
exposure. The use of new radiolabeled tracers also requires on-site facilities with 
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automation of manufacturing, a process which may well be challenging and costly 
due to complex synthesis protocols. The high costs associated with PET tracer 
synthesis as well as the installation and maintenance of PET scanners frequently 
results in PET research being confined to specialized well-funded institutions with a 
historical focus on a particular area of research, most usually in oncology. These 
high startup costs and lack of access to novel PET tracers can severely restrict 
research in novel areas and the progress towards clinical translation. Table 3 
summarizes many of the key obstacles that may hamper the translation of PET 
ligands into the clinic. 
 
 
 
 
 
Table 2. Key examples of inflammatory biomarkers targeted by radiolabeled 
small molecules 
Target Tracer(s) FDA/CE 
approved 
(commerci
ally 
available) 
Disease(s) 
and study 
type 
Comments Reference(s) 
Somastatin 
receptor 
(SSTR) 
68
Ga- 
DOTATATE 
(PET) 
Approved 
for detection 
of SSTR 
Atherosclerosis 
(clinical) 
68
Ga-DOTATATE offers 
superior coronary 
imaging, excellent 
Tarkin et al., 
2017 
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containing 
neuroendori
ne tumors 
(Yes) 
macrophage specificity 
and better power to 
discriminate high-risk 
versus low-risk 
coronary lesions than 
18
F-FDG 
Translocator 
protein 
(TSPO) 
11
C- and 
18
F- 
labeled 
PK11195 or 
structurally 
similar 
molecules 
(PET) 
 
125I
iodo-DPA-
713 
(SPECT) 
No (Yes) 
 
 
 
 
 
 
 
No (No) 
Vasculitis 
(clinical) 
 
 
Stroke (clinical) 
 
 
Alzheimer’s 
(pre-clinical) 
Visualized 
macrophages in 
inflamed artery walls 
 
Detected microglial 
activation in the brains 
of stroke patients 
 
Constant increase in 
uptake in brain regions 
displaying progression 
of Alzheimer’s disease 
in a mouse model 
Lamare et al., 
2011 
 
 
Gulyas et al., 
2012 
 
 
Maeda et al., 
2011 
VCAM-1 
18
F-4V (PET) 
99m
Tc-
cAbVCAM1-5 
peptide 
 
 
 
99m
Tc- 
B2702p1 
nanobody 
No (No) 
 
 
 
 
 
 
No (No) 
Atherosclerosis 
and myocardial 
infarction 
model 
(pre-clinical) 
Used in apoE
-/-
 mouse 
models of 
atherosclerosis to 
target plaque with 
increased uptake at 
plaque sites.  
 
99m
Tc-peptide and 
nanobody targeted 
molecules show higher 
Nahrendorf et 
al., 2009 
 
 
 
 
 
Broisat et al., 
2012 
Dimastromatte
Jo
urn
al 
Pr
-pr
oo
f
Journal Pre-proof
  45 
(SPECT) affinity than 
18
F-4V o et al., 2013 
Vascular 
adhesion 
protein 1 
(VAP-1) 
 
68
Ga-
DOTAVAP-1 
and 
structurally 
similar 
molecules 
 
 
 
68
G-DOTA-
Siglec-9 
(PET) 
No (No) 
 
 
 
 
 
 
 
 
No (No) 
Tumor bearing 
animal model in 
association 
with 
inflammation 
(pre-clinical) 
 
 
 
Atherosclerosis 
(pre-clinical) 
68
Ga-DOTAVAP-1 can 
show better 
discrimination of 
inflammation versus, for 
example, tumor cell 
uptake, while 
18
F-FDG 
fails to separate the 
signal source 
 
PET signal was 
specifically increased in 
atherosclerotic aorta 
and could be 
attenuated by blocking 
VAP-1 
Autio et al., 
2010 
 
 
 
 
 
 
 
Silvola et al., 
2016 
αvβ3 integrin 
18
F-RGD 
 
 
 
 
 
 
 
 
 
No (No) 
 
 
 
 
 
 
 
 
 
Atherosclerosis 
(clinical) 
 
 
 
 
 
 
 
 
18
F-RGD showed 
specific uptake in 
human carotid vessels 
that displayed 
narrowing (stenosis) 
but not in contralateral 
healthy vessels. 
Results correlated with 
macrophage density 
and blood vessel 
Beer et al., 
2014 
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18
F-flotegatide  
18
F-fluciclatide 
 (PET) 
 
 
No (No) 
 
 
Atherosclerosis 
(pre-clinical) 
 
 
 
 
 
 
Myocardial 
infarction 
(clinical) 
formation 
 
18
F-flotegatide, a more 
easily manufactured 
tracer than 
18
F-RGD, is 
readily imaged in the 
plaques of 
atherosclerotic mice 
with signal intensity 
correlating with 
macrophage infiltration 
and integrin expression 
 
18
F-Fluciclatide uptake 
is increased at sites 
of recent MI acting as a 
biomarker of cardiac 
repair and 
predicting regions of 
recovery 
 
 
Su et al., 2014 
 
 
 
 
 
 
 
 
 
 
Jenkins et al., 
2017 
Cathepsin A 
64
Cu-BMV101
 
No (No) Atherosclerosis 
(pre-clinical) 
Could non-invasively 
image activated 
macrophages directly 
releasing plaque-
destabilizing 
compounds. 
Also developed optical 
fluorescent cathepsin 
probes for optical 
Withana et al., 
2016 
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imaging
 
Matrix 
Metalloprotein
ases 
123
I or 
125
I-
CGS 27023A 
99m
Tc-RP-805 
(SPECT) 
No (No) Atherosclerosis 
(pre-clinical) 
Allows visualization of 
plaque formation in 
mouse models 
Fujimoto et al., 
2008 
Ohshima et al., 
2009 
Lectin-like 
oxidized LDL 
receptor-1 
(LOX-1) 
99m
Tc-LOX-1-
mAb 
 
 
 
 
 
 
111
In-
liposome–
LOX-1 
antibody-DiI 
(SPECT) 
No (No) 
 
 
 
 
 
 
 
No (No) 
Atherosclerosis 
(pre-clinical) 
99m
Tc-LOX-1-mAb 
antibody was found to 
effectively target 
macrophage dense 
atherosclerotic lesions 
in hyperlipidemic 
rabbits 
 
111
In-liposome–LOX-1 
antibody-DiI (a 
liposome encapsulated 
LOX-1 antibody) Shown 
to selectively bind to 
plaque shoulder – an 
area frequently 
associated with plaque 
rupture in humans – in 
two murine models of 
atherosclerosis 
Ishino et al., 
2008 
 
 
 
 
 
 
Li et al., 2010 
CD20 ¹²⁴ I-rituximab 
(PET) 
No (No) RA  
(clinical) 
5 RA patients were 
treated with B cell 
specific ¹²⁴ I-rituximab 
imaging agent. B cells 
Tran et al., 
2011 
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were detected within 
the joint, but the clinical 
significance based on 
such a small cohort is 
unclear 
IL-2 receptor 
18
F-FB-IL-
2(PET) 
No (Yes) Mouse tumor 
model 
(pre-clinical) 
Proved useful in 
monitoring T cell 
infiltration into tumors 
as a response to 
chemotherapy. 
Potential to guide 
therapeutics 
Hartimath et 
al., 2017 
GPIIb/IIIa 
18
F-GP1 
(PET) 
No (Yes) Model of 
arterial injury 
(pre-clinical) 
 
 
 
 
Thrombosis 
(clinical) 
Strong signal observed 
specifically in areas of 
arterial injury 
associated with 
thrombus formation in 
primates. 
 
Completed phase 1 
clinical trial for imaging 
thrombosis 
(ClinicalTrials.gov 
Identifier: 
NCT02864810) 
Lohrke et al., 
2017 
P2X 
purinoceptor 
7 (P2X7 
 
18
F-EFB 
(PET) 
No (No) Systemic rat 
model of 
inflammation 
18
F-EFB is the first 
P2X7 receptor ligand to 
cross the blood-brain 
Fantoni et al., 
2017 
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receptor) (LPS injection) 
(pre-clinical) 
barrier and was 
detected in the brains 
of rats injected 
systemically with LPS. 
This opens new 
avenues for exploring 
an important marker of 
neuroinflammation in 
the brain 
CXCR4 
68
Ga-
pentixafor 
(PET) 
No (No) Atherosclerosis 
(clinical) 
 
 
 
 
 
Atherosclerosis 
(clinical) 
Patients with higher 
arterial binding of 
68
Ga-
pentixafor displayed 
more co-morbidities 
and history of CVD 
events 
 
68
Ga-pentixafor arterial 
uptake was correlated 
with plaque severity, 
CVD risk factors and 
prior adverse CVD 
events (Figure 2) 
Li et al., 2018 
 
 
 
 
 
 
Weiberg et al., 
2018 
Mannose 
receptor 
 
 
 
 
 
111
In-
tilmanocept  
(SPECT) 
 
 
 
 
Yes 
(for lymph 
node 
mapping) 
(Yes) 
 
 
Atherosclerosis 
(pre-clinical) 
Specific uptake of 
111
In-
tilmanocept was 
observed in the plaques 
of apoE
-/-
 mice. 
Blocking mannose 
receptors attenuated 
signal intensity. 
Varasteh et al., 
2017 
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Receptor for 
advanced 
glycation end-
products 
(RAGE) 
64
Cu-Rho-G4-
CML NP 
(PET/Optical) 
No (No) Hindlimb 
ischaemia 
(pre-clinical) 
The use of a multi-
modal NP (PET/optical) 
allowed whole body 
imaging in mice with 
the greatest 
concentrations found in 
the ischaemic hindlimb. 
The larger size of the 
NP may also allow a 
drug payload for 
therapeutic utility. 
Konopka et al., 
2018 
IL-1β and 
CD11b 
89
Zr-α-IL-1β 
and 
89
Zr-α-
CD11b (PET) 
No (No) IBD (pre-
clinical) 
Il-1β and CD11b 
(macrophage marker) 
were found to increase 
in a murine model of 
IBD with IL-1β levels 
correlating with disease 
severity. PET was able 
to out perform MRI and 
translation to humans 
may offer a non-
invasive diagnostic tool 
in comparison with 
endoscopy.  
Dmochowska 
et al., 2018 
LFA-1 
111
In-DOTA-
butylamino-
NorBIRT 
No (No) Atherosclerosis 
(pre-clinical) 
SPECT/CT imaging of 
apoE
-/-
 mice revealed 
the tracers were bound 
Meester et al., 
2018 
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(DANBIRT) 
(SPECT) 
to CD68 macrophages 
and other LFA-1 
expressing immune 
cells within the growing 
atheromas.  
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Table 3. PET: Barriers from tracer design to clinical practice 
 
*MRC Review of ‘Positron Emission Tomography (PET) within the Medical Imaging 
Research Landscape’, 2017. 
  
Cost Expertise Collaboration Funding 
 Tracer synthesis 
 Infrastructure 
 Scans 
 Maintenance 
 
 Radiochemistry 
 GMP 
 Radiologists 
 Lack of PET uptake 
beyond core areas* 
 
 Tracer development 
 Scanning protocols & 
data collection 
 Clinical-trial co-
ordination 
 Lack of multi-discipline 
approaches (playing to 
strengths)* 
 
 Challenging to secure 
for novel PET 
tracers* 
 Not considered a 
priority area by 
funding bodies* 
 Lack of clarity on 
which body has remit 
for funding* 
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Figure 1. Selected examples of PET imaging biomarkers related to 
inflammation. Reprinted from Wu et al. PET imaging of inflammation biomarkers. 
Theranostics. 2013;3:448-66. Distributed under a Creative Commons Attribution (CC BY-
NC) license. 
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Figure 2. 68Ga-pentixafor PET/CT images of abdominal aorta in 64-y-old man. 
CT (A and C) and PET/CT (B and D) images in transaxial (A and B) and coronal (C 
and D) views show 68Gapentixafor uptake in calcified atherosclerotic lesion (arrows) 
coincident with calcification. Figure and figure legend reprinted from Weiberg et al. 
Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in 
Atherosclerotic Plaque Using (68)Ga-Pentixafor PET: Correlation with 
Cardiovascular Risk Factors and Calcified Plaque Burden. J Nucl Med. 2018;59:266-
272. Copyright of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). 
 
2.7 Acoustic Imaging (contrast-enhanced ultrasound (CEUS)) 
US is an established medical imaging technology and one of the most used 
diagnostic modalities in the clinic. US is commonly used for abdominal, testicular, 
breast, neck and musculoskeletal examinations in its non-invasive form. US can also 
be applied to assess the status of blood vessels and determine the presence and 
gross morphology of atherosclerotic plaques and thrombus. Although this can be 
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assessed non-invasively, improved invasive forms of US (IVUS) are being 
developed. IVUS uses a catheter-based approach for imaging the wall of blood 
vessels. It’s high spatial resolution and ability to discriminate plaque components in a 
superior manner to invasive angiography has helped transform our understanding of 
atherosclerosis. IVUS can be thought of as a moderately high resolution (150-250 
µm) morphological imaging tool, rather than a true molecular imaging tool. Therefore, 
a discussion of standard (non-contrast enhanced) IVUS here is not warranted. For 
true molecular imaging, as per all the techniques described so far, all forms of US 
require the use of contrast agents (contrast-enhanced ultrasound; CEUS). US 
contrast agents (UCAs) generate resonance reflection signals, which provide high 
signal to noise based on increased acoustic scattering properties. The most common 
contrast agents in US are gas filled microbubbles. Microbubbles have a size of 1-8 
µM which confines their location to the circulation, making them excellent UCAs for 
imaging the vasculature, allowing visualization of micro-vessels normally hidden on 
standard Doppler US. In brief, microbubbles all share 3 properties: 1) a core 
containing a compressible and acoustically reflective gas; 2) a protective 
biocompatible coating (shell) and 3) a diameter of 1-8 µM allowing body wide 
vasculature perfusion. While microbubbles dominate the CEUS landscape, other 
nanoscale UCAs have been developed and are currently being investigated in pre-
clinical research. These include echogenic liposomes (ELIPs), nanobubbles, 
nanodroplets and nanoparticles. The use of nanoscale UCAs opens up avenues to 
target molecules beyond the vessel wall, owing to their smaller size and ability to 
enter tumors or inflammatory sites through the EPR effect. Although less well tested, 
they can also be used as vehicles for drug delivery. 
Clinical use 
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A number of microbubble UCAs have been developed and several are commercially 
available for clinical use and there now exists a long safety record of use in humans 
(Schinkel et al., 2016). This high safety threshold is due to microbubbles being able 
to pass into the pulmonary circulation. After injection of microbubbles, imaging can 
begin after a few minutes. Following acoustic shattering of the microbubbles, the 
shell is safely removed via the reticuloendothelial system and the gases are released 
via the lungs (Schinkel et al., 2016). The clinically approved UCAs are all untargeted 
microbubbles that have found clinical use in improving US resolution of organ 
abnormalities (Guvener et al., 2017). US has also made dramatic advances in areas 
of inflammation medicine e.g. in the field of rheumatology – herein US together with 
power doppler is now used routinely to detect synovial inflammation, tendon damage 
/ inflammation and even to provide preliminary evidence of bone erosion. 
Furthermore, the use of both non-contrast and CEUS for assessing gastrointestinal 
(GI) disorders including IBD is increasing within the clinic. US can detect structural 
changes in the bowel and surrounding mesentery indicative of inflammatory 
processes while the use of contrast agents enhances diagnostic sensitivity and the 
distinguishing features of focal inflammation in Crohn’s disease (Kucharzik et al., 
2017). Although US imaging of the GI tract can be more challenging than other 
organs due to the presence of gas artifacts, it can be a valuable, safer and more 
cost-effective method of GI imaging than other clinical modalities (Muradali et al., 
2015; Kucharzik et al., 2017). No clinically approved use currently exists for 
molecular CEUS imaging. 
Pre-clinical use and in-human trials 
Although the clinical use of CEUS is yet to reach the level of molecular imaging, the 
first in-human clinical trial of targeted molecular ultrasound has now been completed 
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(Willmann et al., 2017) and involved microbubbles (1.5 µM diameter, a 
perfluorobutane/nitrogen core, surrounded by a phospholipid shell) targeted to 
kinase insert domain receptor (KDR) (Abou-Elkacem et al., 2015), a key regulator of 
neoangiogenesis which is expressed on several cancers including ovarian and 
breast. The imaging agent was well tolerated by 40 patients and US molecular 
imaging showed good correlation with histological analysis of biopsy samples. 
Importantly, the safety profile of the trial (in which no patients withdrew due to side 
effects) was similar to that reported for a non-targeted UCA (BR38) (Schneider et al., 
2011) indicating that the addition of targeting ligands may not substantially change 
the in vivo profile of the UCA. Pre-clinical imaging of CEUS in inflammatory 
conditions has produced some fruitful results with advances in detection, image 
processing and quantification using protocols based on the destruction-
replenishment method and acoustic radiation force (ARF) imaging (Abou-Elkacem et 
al., 2015). 
Adhesion molecules have been a keen area of exploration for targeted UCAs in 
inflammatory disease including IBD and atherosclerosis. We will now briefly consider 
each of these diseases in turn: 
US could be employed alongside CT, MRI and endoscopy to offer earlier diagnosis 
and identify treatment responders from non-responders in the case of IBD where 
endoscopy is supplemented with medical imaging (particularly CT but also MRI). As 
an example, microbubbles targeted to adhesion molecules have been used in animal 
models of colitis, including the use of dual-targeted (P- and E-selectin) UCAs (Wang 
et al., 2013). This approach of dual-targeting adhesion molecules shows very close 
correlation with ex vivo histology in terms of grading the extent and stage of 
inflammation that could justify the clinical non-invasive use of CEUS for staging IBD 
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and quantifying the inflammation present using a molecular imaging modality that 
offers greater speed and more tolerable contrast agents than CT and MRI. Moving 
this prospect closer to reality was the study by Wang et al., 2015 using the same 
clinical grade dual-targeted microbubble as used previously. In a porcine model of 
ileitis, the authors demonstrated the feasibility of using CEUS to detect intestinal 
inflammation (Figure 3). The novelty of this approach was the use of a clinical US 
scanner on a large animal, an important step towards translating a quantitative 
molecular imaging approach for inflammatory bowel conditions into the clinic. 
VCAM-1 presents early in atherosclerosis, being present on endothelial cells even 
before the first signs of plaque formation. VCAM-1 targeted microbubbles were able 
to evaluate the different stages of atherosclerosis in mice. Furthermore, reductions in 
VCAM-1 intensity could also be used as a marker of efficacy of statin therapy 
(Kaufmann et al., 2007; Khanicheh et al., 2013). Other molecules to have been 
successfully targeted using microbubbles include ICAM-1 on inflamed endothelium 
(Wu et al., 2013b) and platelet-endothelial cell interactions using microbubbles 
targeted against glycoprotein-Ibα (GPIbα) on platelets and von Williebrand factor 
(VWF) on endothelial cells (Shim et al., 2015), which may help in dissecting the role 
of platelets in the initiation of atherosclerosis and in the detection of thrombotic 
events in late stage pathology. In addition to detecting thrombotic events, CEUS may 
be used to monitor response to treatments that induce reduction in thrombus 
size/formation (thrombolysis) (Wang et al., 2012). Further information on the 
comparison of US with other modalities for imaging atherothrombosis has been 
described elsewhere (Wang and Peter, 2017). A recent advance in CEUS signaling 
employed the ARF technique mentioned above in mice. Not only is this method 
quantitative, it reduces imaging times substantially. Indeed, the use of VCAM-1 or P-
Jo
urn
al 
Pr
e-p
oo
f
Journal Pre-proof
  59 
selectin targeted microbubbles in a murine vascular inflammatory model resulted in 
significant detection of adhesion molecules in the abdominal aorta and an ability to 
discriminate mice with inflammation from control animals in just 180s scanning time 
(Wang et al., 2017). 
A final example of targeted microbubble US in inflammatory disease comes from 
myocarditis, an inflammatory heart condition not associated with ischemia. 
Endomyocardial biopsy is employed for diagnosis yet is an invasive procedure and 
has relatively poor diagnostic prediction. Microbubbles targeted to CD4+ T cells and 
inflamed endothelium (two hallmark inflammatory changes in myocarditis) have been 
used in a mouse model of the disease. In addition, a third microbubble targeted to a 
generic marker on all immune cells was also employed (Steinl et al., 2016). Using 
CEUS, the authors could detect increased signal from the targeted microbubbles in 
animals with moderate disease with signal increasing with disease severity. 
Furthermore, it was the first demonstration that targeted microbubbles could be used 
to detect CD4+ T cell infiltration into an inflammatory site (Steinl et al., 2016). 
While the transcutaneous non-invasive CEUS studies above used targeted 
microbubbles as UCAs, most studies utilizing contrast enhanced IVUS have 
employed targeted perfluocarbon nanoemulsions or liposomes, rather than 
microbubbles. Studies have included the detection of ICAM-1 (Demos et al., 1999) 
and tissue factor (Lanza et al., 2000) in porcine atherosclerotic arteries. A more 
comprehensive study involved the use of liposomes conjugated to 5 markers of 
inflammation and thrombosis in an atherosclerotic swine model. IVUS imaging was 
performed at 20 MHz and results correlated well with post-mortem histological 
analysis. It should be pointed out that this was not a multiplexing experiment. Each 
liposome preparation had only one targeting ligand and each animal only received 
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one liposome preparation (Hamilton et al., 2004). Nevertheless, these studies 
suggest that IVUS with targeted UCAs could be used to better detect and 
characterize vascular injury and atherosclerosis over standard non-contrast 
enhanced IVUS. 
Theranostics 
Therapeutic delivery of drugs via UCAs is an attractive option. Theoretically, a 3 µM 
wide microbubble could carry millions of proteins or small molecules and these 
carriers display favorable safety profiles, confirmed by their long history of clinical 
use. The next issues to address after safety are technical, such as ensuring delivery 
of the UCA to the intended site (such as via molecular targeting or EPR effect) and 
finally, release of the payload in a manner that is not destructive to the target tissue. 
The process most investigated for microbubble-based drug delivery is sonoporation. 
A detailed explanation of this process can be found in Castle et al., 2013. In brief, 
microbubbles undergo oscillation upon exposure to acoustic energy. At high 
amplitude exposure, these oscillations expand in intensity and the shell of the 
microbubble can rupture causing release of the core materials. This process can 
serve as the release mechanism for the drug. When an oscillating microbubble is in 
close proximity to a cell (such as bound via molecular targeting or forced near to the 
vessel wall by the ARF process), transient, reversible increases in the permeability of 
the cell membrane can occur due to the interaction of acoustic energy and the 
oscillating microbubble. When the pulse sequence is controlled, cells can undergo 
reversible permeability without loss of viability (Juffermans et al., 2006). The use of 
US and microbubbles for therapeutic drug delivery has already progressed to human 
case studies and even clinical trials in the fields of cancer (Dimcevski et al., 2016) 
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and for promoting drug delivery through the blood brain barrier (ClinicalTrials.gov 
Identifier: NCT02343991). 
UCAs have also been employed as theranostic agents with a view to utilize them as 
carriers of thrombolytic drugs to thrombotic areas of the vasculature. In a swine 
thrombosis model, Culp et al., 2004 demonstrated that microbubbles tagged with the 
GP IIb/IIIa receptor inhibitor eptifibatide (a thrombolytic drug) caused clot dissolution 
in 6 of 8 pigs following transcutaneous US while 0 of 7 pigs treated with eptifibatide 
alone showed clot dissolution. It has been demonstrated that microbubbles passing 
over an intravascular thrombosis can induce dissolution of the clot when a high 
mechanical index US pulse is employed (Xie et al., 2009b). An important 
development by Wang et al., 2016 involved the use of theranostic microbubbles for 
simultaneous detection, thrombolysis and monitoring of response via a single dual-
conjugated microbubble. The microbubbles were conjugated firstly with the same 
novel single chain antibody directed against GP IIb/IIIa (Wang et al., 2012) along 
with urokinase plasminogen activator (a thrombolytic agent). These theranostic 
particles were utilized for US imaging in the carotid arteries of a mouse thrombosis 
model where they performed a multi-functional role in detecting thrombi, reducing 
thrombus size and acting as readout of the efficacy of the conjugated urokinase 
plasminogen activator. When compared with commercial urokinase alone, the 
microbubbles were just as effective but with a better safety profile owing to greatly 
reduced bleeding times compared with urokinase alone. This is significant as the 
increased risk of bleeding is often a contraindication against the use of urokinase 
and similar thrombolytic agents in many patients with myocardial infarction and 
stroke. US targeted microbubbles have also been employed in conjunction with 
liposome carrying drugs to improve local delivery via ultrasound induced cavitation. 
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Sheng et al., 2018 demonstrated that liposomes loaded with basic fibroblast growth 
factor (bFGF) could be used to increase the delivery of bFGF to the kidney of 
diabetic rats and that tissue delivery of bFGF was enhanced in the presence of focal 
microbubble destruction within the kidney (causing greater drug permeability). This 
resulted in a reduction in inflammation and improvement of renal function. Such a 
dual approach can not only improve residence times of reagents such as bFGF, 
which otherwise have short circulating half-lives, but can also increase the uptake of 
drugs specifically in the target organ (Sheng et al., 2018). 
Microbubbles can also be used for the delivery of genes to target tissues (gene 
therapy). With regard to inflammatory diseases, diabetes has been the main focus of 
this approach to date with microbubble based approaches being applied to 
successfully deliver proinsulin genes to the pancreas in rat models (Chen et al., 
2006; Chen et al., 2010) with optimized gene delivery inducing almost complete 
recovery of the β-cell population that persisted for at least 6 months (Chen et al., 
2012), a promising result that offers a safer delivery vehicle of genes to tissue 
compared with viral based methods. Successful use of US targeted microbubbles 
has also been demonstrated to reduce clinical scores in a rat model of arthritis with 
microbubbles providing local delivery of plasmids encoding the tumor necrosis factor 
(TNF)-α receptor (TNFR) gene (Wang et al., 2019). 
IVUS has also been deployed for therapeutic purposes both ex vivo and in vivo. ARF 
uses the energy/momentum of acoustic waves to propagate particles in the 
directional flow of the energy (Dayton et al., 2002) and can therefore be used to 
direct drug delivery to specific areas of pathology. When combined with 
microbubbles, an IVUS catheter with a diameter compatible with human coronary 
arteries was found to function in a model system involving delivery of a fluorescent 
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small molecule to swine arteries ex vivo (Kilroy et al., 2014a) and in vivo (Kilroy et 
al., 2014b). Importantly, fluorophore delivery was localized to the area where the 
ARF pulse was employed (Kilroy et al., 2014b) thereby demonstrating the feasibility 
of guided delivery of drugs to focal areas of the artery wall. A similar device was 
used in vivo in a swine following vascular injury induced by balloon angioplasty. 
Arteries treated with rapamycin (immunosuppressant drug) loaded microbubbles and 
subjected to 5.1 MHz IVUS displayed a 50% reduction in neointimal formation when 
compared with arteries treated with rapamycin loaded microbubbles alone (Kilroy et 
al., 2015). 
Advantages and barriers to clinical translation 
US has a number of advantages that may allow expedited advance into the clinic as 
a molecular imaging tool. It is a relatively simple, well-tolerated and safe method of 
imaging that is well accepted in routine clinical practice by both patients and 
clinicians. In comparison with other routinely used imaging modalities such as CT or 
MRI requiring radiologist review, specialized US imaging is typically performed at the 
bedside by specialists requesting the investigation (thus minimizing delays, 
interspecialty variability and chance of miscommunication). The benefits of US use, 
therefore are many and can be summarized as follows: 1) high spatial and temporal 
resolution; 2) no ionizing radiation; 3) real-time data analysis and processing; 4) 
ease of operation; 5) portable; 6) relatively low cost; 7) long established use in clinic; 
8) few side effects; 9) ability to acquire anatomic and molecular information in a 
single scan; 10) good potential for quantitative data; 11) attractive to the clinician 
who is a non expert and in private practice. The short interval between contrast 
agent injection and commencement of imaging is a distinguishing feature of US from 
other modalities. Microbubbles have a very short half-life in vivo (3.5 mins; Willmann 
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et al., 2008). The key advantage to this is that imaging of the bound targeted UCA 
can begin shortly after injection (several minutes), unlike PET or SPECT which 
usually require at least 1 hour between administration of the tracer and 
commencement of imaging (Kircher and Willmann et al., 2012). This feature of 
CEUS also allows repeated scans or additional scans of other anatomical areas 
during the same imaging session. 
Promising pre-clinical work on large animals is driving quantitative guided CEUS 
forward at pace; however, more advanced algorithms will be required for human 
patients to account for variations in US frequency and imaging depths in addition to 
more advanced motion-correction methods to account for motion artifacts (Abou-
Elkacem et al., 2015; Wang et al,. 2017). A limitation of quantitative CEUS is that it 
may preclude the real-time imaging that is such a strong advantage of current clinical 
US; however, this area is constantly evolving with ever more refined systems being 
developed. If US is to be considered a viable alternative to nuclear imaging in clinical 
practice, these techniques will require clinical grade systems with improved 
quantitative volumetric analysis including three- and four- dimensional imaging in the 
presence of UCAs (Castle et al., 2013). A recent technical review on the state of 
three-dimensional real-time US imaging may be of interest to some readers (Huang 
and Zeng, 2017). The examples presented above in relation to guiding and localized 
release of a drug is a major asset for any theranostic modality in achieving 
therapeutic levels of a drug at a target site without potential systemic complications. 
Therefore, utilizing UCAs with site directed US to induce microbubble release only at 
the desired location is of clinical value. 
One significant disadvantage of CEUS compared with optical and vibrational 
modalities is a lack of multiplexing potential within a single scan. This could severely 
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restrict the ability of UCAs to be used to stratify inflammatory diseases and make 
diagnostic decisions. The sequential use of microbubbles targeted to more than one 
inflammatory molecule can provide some extra value in terms of enhanced specificity 
and information but the inability to separate the signal of multiple targeted UCAs in a 
single imaging session is a clear limitation. Another disadvantage already touched 
upon is that the current CEUS imaging landscape is dominated by microbubbles, 
which restricts the disease biomarkers to the endothelium thus reducing the 
spectrum of inflammatory targets available, such as those present on sub-endothelial 
inflammatory cell infiltrates. 
With the first clinical trial for molecular targeted CEUS completed successfully 
(Willmann et al., 2017), this should lead to further and more expansive trials in 
oncology, which will hopefully increase the pace of more sophisticated and accurate 
quantitative software and more robust standardization of treatment regimens that 
could readily transfer to clinical studies looking at inflammatory markers. With fewer 
safety barriers to regulatory authorities, coupled with cost effectiveness compared 
with nuclear imaging, CEUS is well placed as both a diagnostic and theranostic 
molecular imaging tool. Indeed, the studies outlined in this chapter that demonstrate 
UCAs can be efficient carriers of immune-modulating drugs and genes paves the 
way for an exciting future for US as both a site-specific delivery modality combined 
with real-time monitoring of therapeutic outcomes. 
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Figure 3. Dose dependent increase in quantitative US signal in five pigs with 
ileitis. (a) Graph summarizes quantitative US signal intensities (represented as 
signal intensity ratios) observed in five pigs with acute terminal ileitis with increasing 
doses (0.5, 1.0, 2.5, 5.0, 10, and 20 x 108/kg) of dual-selectin–targeted contrast MBs 
(MBSelectin). b.w = body weight. (b) Representative transverse US images obtained 
six times in approximately the same location of an inflamed ileum segment (arrows) 
in one pig show increasing imaging signal (overlaid in red onto the anatomic B-mode 
images) with increasing MBSelectin doses. The different US scans were each 
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separated by a 30-minute pause to allow contrast agent clearance. Figure and figure 
legend reprinted from Wang et al. Quantitative assessment of inflammation in a 
porcine acute terminal ileitis model: US with a molecularly targeted contrast agent. 
Radiology 2015;276:809-817. Permission granted by the Radiological Society of 
North America (RSNA®). 
 
2.8 Optical imaging 
Fluorescence imaging 
Fluorescence imaging involves the detection of emission spectrum from a 
fluorescent molecular probe that has been excited by a laser at an appropriate 
wavelength. Probes can be targeted or not and can act as ‘smart probes’ which are 
molecules that are conditioned to be activated at a particular site within the body, for 
example via enzymatic conversion from a non-fluorescent substrate to a fluorescent 
product. In addition to a ‘yes’ or ‘no’ response as to whether a molecule is present, 
the intensity of the fluorescence produced can be used to measure the activity of the 
catalytic enzyme, thus potentially signifying a shift in disease state (Wildgruber et al., 
2013; Scales et al., 2016). Fluorescent imaging typically utilizes the near-infrared 
spectrum (wavelengths between 650-1000 nm) and is thus referred to as near-
infrared fluorescence (NIRF) imaging (MacRitchie et al., 2018). The advantages of 
imaging at these wavelengths are the lack of photonic absorbance from biological 
components such as hemoglobin, lipids and water, allowing greater depth of 
imaging. There is also less tissue autofluorescence at NIR wavelengths, thereby 
increasing signal to noise ratio and hence specificity (Suter et al., 2011). NIRF 
imaging has a number of advantages including good spatial resolution (rapidly 
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decreasing with depth) and sensitivity, relative low cost, lack of ionizing radiation and 
importantly for disease detection, the ability to discriminate multiple fluorescent 
signals due to discrete emission spectrums. NIRF imaging can be performed ex vivo 
on tissue sections and in vivo, either non-invasively or more commonly via intravital 
microscopy (IVM) or through the use of catheter/probe systems. Improvements in 
NIRF imaging probes are advancing at pace with significant gains in brightness, 
solubility and stability as well as the range of fluorophores available (Hilderbrand and 
Weissleder, 2010). Fluorophores are typically either proteins (e.g. green fluorescent 
protein (GFP)), small molecules or quantum dots (QDs). QDs are small (<10 nm) 
fluorescent NPs typically consisting of a semiconductor metal core encapsulated in a 
shell (usually ZnS or ZnSe) amenable to functionalization and fine tuning of particle 
properties. This ability to modify QDs to improve their properties has made them the 
most valuable imaging tool in NIRF microscopy, having increased brightness and 
narrower emission spectrums than other fluorescent based probes (Stevenson et al., 
2011). 
Photoacoustic imaging (PAI) 
PAI, also referred to as optoacoustics, is an imaging modality that uses nonionizing 
optical radiation and ultrasonic detection. Short laser pulses (typically nanosecond 
long light pulses) directed at tissue creates US waves due to transient thermoelastic 
expansion that can be detected non-invasively by a detector outside the patient. 
Recent advances in both laser technology and detection strategies have seen a 
significant advance in the capability of PAI. By combining the advantages of both 
optical and acoustic imaging, PAI can overcome the main limitation of optical 
technology, namely restricted imaging depths which precludes non-invasive imaging 
of any sub-dermal human tissue. PAI can image in model systems depths in the 5-6 
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cm range and superficial structures can be imaged at a spatial resolution of ~ 5 µM, 
superior to that obtainable from standalone optical microscopy (Li and Chen, 2015). 
Like fluorescence imaging, there is a trade off in PAI between resolution and depth 
with spatial resolution diminishing at deeper depths due to energy 
dissipation/dispersion of the emitted photons through tissue. Certain endogenous 
molecules can be detectable by PAI including melanin and hemoglobin, but these 
are relatively weak absorbers of light and diagnostic use is restricted to a narrow 
range of physiological functions or pathologies such as vascular perfusion or skin 
cancer diagnosis. To increase the intensity and scope of PAI requires the use of 
exogenous contrast agents of which strong light absorbing NPs are the most utilized. 
NPs absorb light from short applied laser pulses, resulting in heating, thermal 
expansion and the emission of broadband US waves that can be detected across a 
range of frequencies by an US transducer. NPs have been utilized in PAI for over 10 
years, but recent developments have led to a 100-fold increase in the detection level 
of contrast agent, bringing photoacoustic sensitivity down to the picomolar range (de 
la Zerda, et al., 2012). A versatile range of nanoscale materials have been tested as 
PAI contrast agents including both organic (melanin, carbon and semiconducting 
polymer based) and inorganic (gold, TiS2) based materials. Detailed descriptions of 
the current probe designs used for photoacoustic/MSOT imaging can be found in 
reviews by Jiang and Pu, 2017 and Guijrat et al., 2017. 
Multispectral optoacoustic tomography (MSOT) 
PAI has a powerful ability to spatially resolve optical energy absorption signatures 
via excitation at a single wavelength. The next step towards a more powerful 
molecular imaging tool is the use of multiple excitation wavelengths to identify 
multiple endogenous or exogenous contrast agents (multiplexing). This method 
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exploits the different absorption properties of the target tracers/molecules. The 
multiplexing capacity of MSOT creates a potentially powerful imaging tool where 
endogenous molecules or external tracers can be identified based on their 
absorption spectra. While MSOT can be used to differentiate endogenous 
photoacoustic detectable molecules, a potentially more important development is the 
capacity for targeted molecular imaging. This requires the use of 
tracers/nanomaterials with steep absorption curves (or spectral bands) that can be 
resolved within a single imaging session through the separation of narrow spectral 
bands. 
Clinical use 
None of the optical techniques just described are used clinically in relation to 
inflammatory disorders. Indeed, only NIRF imaging is used at all on a clinical basis. 
To date, the only clinically approved fluorescent contrast agents are fluorescein, 
methylene blue and indocyanine green (ICG) with ICG being the only compound that 
is actively used for fluorescence imaging (principally for lymph node mapping and 
solid tumor detection). Optical coherence tomography (OCT) is a high-resolution 
morphological imaging tool that is increasingly commonly used clinically for 
measuring the status of blood vessels. OCT offers superior resolution to IVUS when 
phenotyping atherosclerotic plaques, being able to measure the thickness of the 
fibrous cap in addition to providing other more detailed morphological information 
(Fenning and Wilensky, 2014). Despite OCT being a valuable tool in diagnosing and 
investigating atherosclerosis, the Providing Regional Observations to Study 
Predictors of Events in the Coronary Tree (PROSPECT) trial indicated that 
morphological information alone was not sufficient to predict subsequent coronary 
plaque ruptures (Stone et al., 2011) thus highlighting the need for molecular imaging 
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modalities to supplement established technologies. Despite OCT not bring a true 
molecular imaging tool its inclusion here is due to its high spatial resolution to pin 
point regions of interest that when combined with a molecular imaging technique 
such as NIRF, can create powerful multi-modal imaging devices with examples listed 
below. 
Pre-clinical use and in-human trials 
Out of the modalities listed above, NIRF has the most pre-clinical studies in chronic 
inflammatory disease (almost exclusively CVD at a molecular level). These studies 
vary in design and complexity, utilizing a variety of methods, both invasive and non-
invasive to harness the strengths of NIRF imaging and overcome the major 
limitations. 
Fluorescence molecular tomography (FMT), a volumetric imaging technique capable 
of highly sensitive (picomolar level) 3-D detection of fluorescent probes, can improve 
localization and deeper tissue imaging (Ntziachristos et al., 2002). FMT allows 
simultaneous quantitative molecular imaging of one or more tracers labeled with 
dyes operating with distinct NIR spectra and has been employed in pre-clinical 
studies on rodents. Table 4 lists the key studies in the cardiovascular field of NIRF 
imaging that utilize exogenous tracers with both non-invasive and invasive studies 
included. In addition to the studies in Table 4 that employ exogenous tracers, some 
studies have also taken advantage of the naturally occurring NIR fluorescent 
molecules that exist in the body to perform NIR autofluorescence (NIRAF) imaging 
without any external tracer. NIRAF has yielded interest in the fields of cancer, 
ophthalmology and CVD. Combined OCT-NIRAF plaque imaging using an 
intravascular optical fiber catheter has been used in patients undergoing 
percutaneous coronary intervention where NIRAF signal intensity correlated with 
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plaque stage and high macrophage density regions as assessed by OCT (Ughi et 
al., 2016). A later study employing a vulnerable plaque mouse model identified the 
blood breakdown product bilirubin as the source of the autofluorescence in that 
model, with bilirubin resulting from intraplaque hemorrhage (Htun et al., 2017). This 
is an important finding since intraplaque hemorrhage is a key histological feature of 
human plaque instability (Virmani et al., 2005). Combining these data with the patient 
data by Ughi et al., 2016 suggests that in humans bilirubin may also be the source of 
the NIRAF; however, other molecules such as oxidized lipoproteins may also 
contribute and further work will be required to optimize the detection wavelength and 
define in more detail which autofluorescent molecules are present and at what stage 
of pathology in human atherosclerosis. The few studies to date suggest a tantalizing 
prospect for intravascular NIRAF as a modality to reliably detect the vulnerable 
plaque. 
PAI, while combining strong attributes from both optical and acoustic imaging has 
shown a slow development, with few imaging agents tailored to molecular PAI 
(Gargiulo et al., 2016). Early studies using gold-based NPs demonstrated that PAI 
could reliably detect adhesion molecules in cells and isolated atherosclerotic vessels 
(Wang et al., 2009). Gold nanoshells conjugated to VCAM-1 are also able to bind 
endothelial VCAM-1 and be detected by PAI while displaying no toxicity in mice 
(Rouleau et al., 2013). Fluorescence microscopy struggles to provide accurate 
spatial localization which hinders quantification due to scattering effects of the 
photons within tissue. To attempt to localize with high precision activated proteases, 
Razansky et al. (2012) employed MSOT with a protease activatable probe and 
subsequently measured the absorption changes of the activated probe. The authors 
were able to measure with high specificity and spatial location the presence of the 
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activated probe in isolated atherosclerotic human arteries. The added benefit of 
optoacoustics is that it reveals the underlying morphology of the plaque, allowing 
localization of the protease in 3 dimensions (Razansky et al., 2012). 
The fact that the spatial resolution of PAI/MSOT is not affected by scatter is a 
significant advantage over comparative fluorescent approaches. Perhaps the most 
interesting animal study to date utilized an ICG conjugated PEGylated polymer in a 
novel nanoprobe (ICG@PEG-Ag2S) for imaging in mice using an inVision 256 PAI 
system (iThera Medical). ICG@PEG-Ag2S was designed for long residence times 
and being lipophilic in nature, should show preferential homing to atherosclerotic 
plaques. Interestingly, following administration of ICG@PEG-Ag2S, excellent aortic 
localization was demonstrated with signal lasting for up to 24 hours. This was in 
contrast to mice injected with free ICG where signal was 6-fold lower and had 
dissipated by 1 hour. The authors, therefore, had successfully tested a high contrast 
real-time PAI system in an atherosclerotic model (Wu et al., 2016). MSOT has also 
been employed to assess adhesion molecule expression in animal models of RA 
using fluorescently targeted nanocarriers. Using an L-selectin/P-selectin targeted 
probe in arthritic mice, Beziere et al. (2014) were able to non-invasively image the 
arthritic joint at a depth of ~5mm, superior to what could be achieved by 
fluorescence. An imblanace in redox signaling, resulting in enhanced reactive 
oxidant species (ROS) production, is a central component of inflammation, including 
vascular inflammation. Recently, an elegant study employed a dual glutathione 
(GSH)/hydrogen peroxide (H2O2) probe with differential absorbance wavelengths 
allowing a measure of redox status. Use of this probe provided information on both 
oxidant and anti-oxidant levels within the plaque of LDLR-/- and apoE-/- mice, a result 
attributed to changes in macrophage number/activation. Importantly, the information 
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gained from redox status could be used to differentiate stable from unstable plaques 
(Gao et al., 2018). Finally, MSOT has also been used to detect endogenous signs of 
inflammation (predominately oxygenated hemoglobin) in the colon in a mouse model 
of colitis using non-invasive imaging with a resolution of 75 µM. The non-invasive 
imaging results by MSOT correlated well with the diagnostic data obtained from 
colonoscopy (Bhutiani et al., 2017). Turning to human studies, since PAI/MSOT can 
image both oxy and deoxy-hemoglobin (allowing oxygen levels and angiogenesis to 
be assessed) without external contrast agents, PAI imaging of joints in human RA 
patients has revealed the potential of PAI for early non-invasive diagnosis of RA. Jo 
et al. (2017) utilized a novel point-of-care PAI system to measure the oxygenation of 
hemoglobin in the joint tissue of RA patients and healthy subjects. Hypoxia, which is 
a signature feature of the inflamed joint in RA, related to inflammatory cell infiltration 
and oxidative stress, was found to be visualized in the joints of RA patients whereas 
healthy subjects showed significantly higher oxygenated hemoglobin (normoxia) 
(Figure 4). This promising result in 10 patients is currently being expanded upon in a 
clinical trial of 120 RA patients (ClinicalTrials.gov Identifier: NCT00748254). 
Following on from promising results in mice utilizing PAI for imaging the inflamed 
colon, a pilot study is currently underway to investigate the usefulness of MSOT in 
diagnosing inflammatory bowel disease (ClinicalTrials.gov Identifier: NCT02622139). 
Theranostics 
PAI/MSOT is perhaps the only optical imaging technology discussed that has a 
potential therapeutic use due to its extensive utilization of metallic nanoscale NPs 
and its inherent reliance on the induction of heat in the photoacoustic target. Under 
laser irradiation, PAI contrast agents produce heat which can cause thermal ablation 
and death of targeted cells, a process termed photothermal therapy. Hyperthermic 
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approaches can also be used to induce drug release from a nanocarrier at the 
intended release site (Fomina et al., 2012), with the avoidance of potential systemic 
side effects and concentrating the drug locally. In an in vitro thrombus model, the 
acoustic pulse pressure produced under laser excitation creates a cavitation bubble 
which could promote local drug release/delivery into the vessel wall (Shangguan et 
al., 1996). A more recent and potentially elegant multi-modal delivery system was 
created and takes advantage of the fact that the photoacoustic effect is not just 
generated by thermal expansion but also by vaporization. The system involves a 
protein shell carrier loaded with PFC nanodroplets and optically absorbent gold 
nanostructures. Under optical excitation, the heat generated by the gold 
nanostructures induce a liquid to gas phase transition (vaporization) of the PFCs, 
resulting in a strong photoacoustic signal. Since the photoacoustic effect is greater 
through vaporization than thermal expansion, this system offers the potential for 
more powerful PAI as well as a tracer capable of acting as a targeted drug delivery 
vehicle (Wilson et al., 2012). In fact, this process has already been validated in an in 
vivo cancer model using the anti-cancer drug, paclitaxel, in combination with tumor 
cell targeted photoacoustic NPs, with the result being local drug release and tumor 
destruction (Zhong et al., 2016). Other developments include even more complex 
multi-modal NPs for drug delivery and release, the most interesting being a 
fluorescent/PAI/CT compatible NP for photothermal therapy and/or drug/gene 
delivery and such a NP has recently been successfully tested in a murine cancer 
model (Duan et al., 2017). More recently, PAI has been used in combination with 
NIR light to both monitor retention of dexamethasome loaded nanocarriers and to 
induce photothermal release of the drug following injection of the nanocarrier into the 
joint cavity of mice with osteoarthritis. Such an approach allows a targeted high dose 
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administration of an anti-inflammatory compound into the joint with only minimal 
systemic effects (Zhao et al., 2019). 
Advantages and barriers tos clinical translation 
Optical imaging, encompassing all its forms from microscopy to endoscopy and 
specimen/biopsy analysis is the most common clinical imaging tool. Yet, as has been 
outlined throughout this chapter, their use for in vivo imaging is severely restricted by 
poor penetration depths accompanied by decreasing spatial resolutions, lack of 
biocompatible fluorescent probes and challenges in quantification. All these issues 
severely limit the potential for clinical translation. Several methods are being 
developed in an attempt to improve NIRF imaging depths while also allowing 
quantification. FMT-CT has evolved as a tool for quantifying with greater precision 
the anatomical location of fluorescent imaging agents. While FMT-CT offers a high 
sensitivity tool for quantitative assessment of a fluorescent signal within a region of 
interest, it doesn’t overcome the poor spatial resolution of fluorescence at deeper 
imaging depths, hence only large changes in pathology can be discerned and it 
becomes impossible to localize the signal precisely without doing subsequent ex vivo 
correlation experiments on isolated vessels or tissue sections thus negating any 
benefit of non-invasive imaging. 
Since depth of imaging is not of such high importance in intravascular NIRF, it is 
much more feasible that imaging of arteries -with all the added molecular detail that 
NIRF can bring, especially when combined with OCT- will be the first clinical use of 
NIRF in assessing an inflammatory disease (atherosclerosis). Before this can 
happen though, it needs to be established in controlled trials that NIRF can 
demonstrate better risk stratification than current methods such as coronary artery 
calcium scoring and FRS.  
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PAI/MSOT is now a fast-moving technology with significant potential in the field of 
medical imaging. It can offer higher spatial resolution than NIRF microscopy, can 
provide anatomic and functional information in the absence of external contrast 
agents or additional hybrid modalities, which can be extended to molecular imaging 
by targeted external contrast agents such as metallic NP based tracers. 
Furthermore, MSOT extends PAI to a multiplexing modality by being able to 
distinguish different spectral signatures and therefore assessing different molecular 
pathways or events (Gujrati et al., 2017). It is clear that PAI differentiates itself from 
other optical modalities by offering high resolution imaging with mm to cm 
penetration depths. PAI utilizing NIR light can move beyond NIRF imaging (depths 
~0.5-1 mm where spatial resolutions can be sub 20 µM) (Zhang et al., 2006) 
extending out to several cms while maintaining resolutions in the 100 µM range (Ma 
et al., 2009). Entire body imaging is possible on small rodents, in particular albino 
mice, which lack melanocytes whereas the more pigmented skin in, for example, 
C57BL/6 mice may result in interference from superficial melanin when imaging 
deeper tissues. In humans, larger organs including human breast (Ermilov et al., 
2009) have also been visualized. Since PAI receives acoustic signals, it shares the 
advantage of real-time imaging with US, allowing dynamic processes to be viewed in 
living organisms. The advantages of PAI and in particular MSOT, in addition to real-
time imaging and improved spatial resolution, are versatile contrast agents, 
portability, scalability and cost effectiveness coupled with a lack of ionizing radiation 
(Ntziachristos and Razansky, 2010). Like NIRF imaging, the major limitation 
regarding human use of PAI is penetration (sensitivity of detection at increasing 
depth). While the spatial resolution of PAI has been studied in some detail, less 
studied is the sensitivity of detection of contrast agents. In vivo estimates vary from 
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study to study ranging from sub nM (del la Zerda et al., 2010; del la Zerda et al., 
2012) to low nM detection (Haedicke et al., 2017). Variables that effect sensitivity 
include depth, type of contrast agent, magnitude of light applied, and the US detector 
employed. Like NIRF, in terms of PAI being used for in human imaging of 
inflammatory diseases, this may initially involve intravascular (CVD) or endoscopic 
(IBD) devices where the restricted depth and other tissue penetration limitations are 
not a limiting factor. In these circumstances, the high resolution, multiplexing 
capability of MSOT could bring significant clinical value over current techniques such 
as OCT or IVUS in identifying cell types or inflammatory signatures within the tissue, 
thus reflecting the stage and severity of the pathology. Additionally, PAI has been 
demonstrated to be capable of imaging human joints, potentially bringing arthritis into 
its sphere of clinical utility (Wang et al., 2007). One last area that requires extensive 
research is quantification of the photoacoustic signal. MSOT, in principle can identify 
multiple biomarkers by their absorption spectra. However, there are challenges 
associated with multi-wavelength measurements arriving through biological tissue. 
Tissue attenuation of light is directly related to depth and wavelength and requires 
sophisticated algorithms to retrieve and quantify the signal, a feature made more 
complex when multi-spectral analysis is required. However, significant progress is 
being made in improving the software data processing of PAI and indeed, NIRF 
imaging. The goal then is the setting of common standards between instruments and 
institutions that would be required for clinical level use, alongside stable laser setups 
and ease of use hardware and software. 
Clinical trials in PAI are now underway (predominately first in-human or phase I) and 
these will focus on feasibility, safety and proof of concept effectiveness. While many 
of these trials are in oncology (as described by Valluru et al., 2016), most 
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interestingly for the reader are the two trials outlined above in respect of RA and IBD. 
Early results from RA are promising as described by Jo et al. (2017). Optimism too is 
warranted with the first results to emerge from the clinical trial in IBD where MSOT 
analysis of hemoglobin in the colon wall could distinguish between active Crohn’s 
disease and patients in remission (Knieling et al., 2017). If the outcome of these 
trials and other phase 1 trials are successful, then larger phase II trials should follow 
to demonstrate value and reimbursement pathways for regulatory bodies that will 
determine clinical translation potential assuming biological effectiveness and safety 
meet the endpoint criteria. 
 
 
 
 
Table 4. Essential NIRF imaging publications on CVD 
Target Tracer(s) FDA/CE 
approved 
(commerci
ally 
available) 
Disease(s) and 
study type 
Comments Reference(s) 
Ox-LDL LO1-750 No (No) Atherosclerosis 
(pre-clinical) 
Utilized a natural anti-
Ox-LDL antibody 
conjugated to a 
fluorescence dye for 
non-invasive in vivo 
Khamis et al., 
2016 
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FMT-CT quantitative 
imaging of 
atherosclerosis in 
mouse models and via 
intravascular NIRF in a 
rabbit model 
VCAM-1 VNP 
(VHSPNKK-
modified 
multi-modal 
magnetofluor
escent NP) 
No (No) Atherosclerosis 
(pre-clinical) 
Use a VCAM-1 peptide 
targeted 
magnetofluorescent 
NP to target activated 
endothelium in 
atherosclerotic mice 
that are detectable by 
MRI and fluorescent 
IVM 
Kelly et al., 
2005 
Non-targeted 
64
Cu-TNP 
(Triple 
modality 
PET/MRI/fluor
escence NP) 
No (No) Atherosclerosis 
(pre-clinical) 
First tri-modal NP 
tested in vivo for 
detecting macrophages 
in apoE
-/-
 mice. Each 
modality showed good 
inter-mode correlation 
with doses below those 
used clinically in PET 
studies 
Nahrendorf et 
al., 2008 
Cysteine-
protease 
ProSense750 
(Cysteine-
protease 
activatable 
No (Yes) Atherosclerosis 
(pre-clinical) 
Employed a NIRF 
probe on a clinical 
grade catheter to 
measure protease 
Jaffer et al., 
2008 
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probe) activity in the aorta of 
atherosclerotic rabbits 
in real-time following 
injection of protease 
activatable probe 
Cysteine-
protease 
Prosense 
VM110 
(Cysteine-
protease 
activatable 
probe) 
No (Yes) Atherosclerosis 
(pre-clinical) 
Similar study type to 
that performed above 
by Jaffer et al., 2008. 
Important advances 
towards clinical 
translation include: 
1) a NIRF probe 
capable of imaging 
360° with accurate 
geometry and co-
registration with IVUS 
2) Able to image larger 
caliber (human scale 
coronary) arteries in 
blood flow 
3) Use of clinical 
monorail catheter 
Jaffer et al., 
2011 
Non-targeted ICG Yes (Yes) Atherosclerosis 
(pre-clinical) 
20 min injection of sub-
clinical doses of ICG 
revealed highly 
selective uptake in 
atherosclerotic lesions 
in a rabbit model, both 
via ex vivo imaging and 
Vinegoni et al., 
2011 
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intravascular catheter 
 
Key finding is that an 
FDA approved imaging 
agent can detect 
plaques in a rabbit 
CVD model at a 
dose/kg that is safe for 
humans 
Passive 
uptake by 
atheroscleroti
c plaque 
ICG Yes (Yes) Atherosclerosis 
(pre-clinical) 
Tested a dual OCT-
NIRF intravascular 
catheter with ICG 
contrast agent in swine 
models of 
atherosclerosis and 
arterial injury. While 
NIRF could assess 
plaque severity and 
inflammation, ICG 
showed lack of 
specificity in plaque 
(due to its lack of fine 
targeting) 
Kim et al., 
2016a 
Mannose 
receptors  
MMR-
Cy5.5/Cy7 
(fluorescent 
macrophage 
mannose 
receptor 
No (No) Atherosclerosis  
 (Pre-clinical) 
Authors employed both 
IVM and intravascular 
dual OCT-NIRF probes 
to detect plaque 
macrophages via a 
fluorescent NP 
Kim et al., 
2016b 
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targeted NP) targeted to mannose 
receptors. The probe 
demonstrated high 
affinity for 
macrophages and low 
toxicity 
Not targeted ICG Yes (Yes) Atherosclerosis 
(Clinical) 
First in-human test of 
ICG for plaque 
imaging. Patients 
undergoing carotid 
endarterectomy 
surgery were 
administered ICG prior 
to removal of arterial 
plaque for ex vivo 
analysis. ICG 
illuminated several 
plaque components 
including endothelial 
disruption, 
macrophage/lipid 
accumulation and 
intraplaque 
hemorrhage 
Verjans et al., 
2016 
αvβ3  IRDye800Cw 
and AF680 
NIR 
fluorescent 
No (Yes) RA (pre-clinical) Successfully imaged 
inflamed joints in a 
mouse model of 
arthritis and modelled 
Bhatnagar et 
al., 2019 
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probes potential clinical 
imaging depths using 
simulations.  
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Figure 4. PA hemoglobin oxygenation (sO2) image superimposed on the gray-scale 
US image of human MCP joint. (A) Imaging result from an unequivocal inflammatory 
MCP joint. (B) Imaging result from a healthy MCP joint. (C) Averaged sO2 levels in 
the joint space: 10 unequivocal inflammatory joints (Arthritis) vs. 10 healthy joints 
(Normal). Figure and figure legend reprinted from Jo et al. A Functional Study of 
Human Inflammatory Arthritis Using Photoacoustic Imaging. Sci Rep. 2017;7:15026. 
Distributed under a Creative Commons CC BY license 
(https://creativecommons.org/licenses/by/4.0/). 
 
2.9 Raman spectroscopy/Surface-enhanced Raman spectroscopy (SERS) 
Raman spectroscopy is a form of vibrational spectroscopy that can provide data 
through molecularly specific spectra which are based on the vibrational energies of 
chemical bonds within molecules following excitation with a light (laser) source. This 
approach can provide detailed information on the molecular composition of cells and 
tissue. Raman spectroscopy can also identify multiple molecules in solution or within 
tissue through a high multiplexing capacity, allowing dynamic changes of molecular 
composition to be followed over time. The spectra produced by biological molecules 
creates a chemical fingerprint of the sample allowing detailed analysis of the 
changing molecular phenotype of a sample at a spatial resolution down to 1 µM 
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(Bunaciu et al., 2017). Classical Raman spectroscopy is limited by low depth (µM 
range) imaging and therefore its use will be confined to ex vivo analysis of 
blood/urine and tissue biopsies or for analysis of skin disorders or placement within 
modified catheters for invasive use; however, advances in Raman technology now 
allow for deeper imaging, making in vivo non-invasive imaging a realistic prospect as 
will be described below. 
Raman spectroscopy is highly capable at characterizing the biochemical changes 
within cells and tissue. Raman generates fingerprint spectra within the 2000-400 cm-
1 wavelength window. Raman obtains spectra from the inelastic scattering of light 
(visible, NIR or UV) from a laser. This is when incident (or arriving) photons from a 
laser interact with molecular vibrations, resulting in the emitted photons having a 
different wavelength and these wavelength shifted photons (inelastically scattered) 
can be used to create molecularly specific fingerprint spectra. Molecular distribution 
maps of proteins and lipids can be created by plotting the signal intensity of a peak 
of interest at each pixel imaged. For imaging beyond superficial tissue, a modified 
form of Raman called spatially offset Raman spectroscopy (SORS) may be 
deployed. These attributes make Raman an attractive tool for non-destructively 
acquiring biological information; however, it does have a major disadvantage, 
namely the inherent weakness of the Raman effect. Only about 1 photon in a million 
undergoes inelastic scattering resulting in poor sensitivity which results in long 
imaging times and an inability to discriminate low-level target analytes from 
background noise. Finally, many biological molecules are spectrally similar requiring 
complex chemometric analysis to separate spectra of interest (MacRitchie et al., 
2018). To overcome the low sensitivity of Raman, two modifications to Raman 
spectroscopy, termed stimulated Raman scattering (SRS) and coherent anti-Stokes 
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Raman scattering (CARS) have been developed. Classical Raman is often referred 
to as spontaneous Raman spectroscopy when used in comparison to these two 
other modifications. Both SRS and CARS are orders of magnitude more sensitive 
than spontaneous Raman, utilize more than one light source and depend on specific 
resonance parameters between the lasers and the molecules being analyzed. A 
detailed explanation of SRS and CARS can be found in a well-written review by 
Tipping et al. (2016). Both SRS and CARS allow rapid image acquisition, a major 
advantage over spontaneous Raman, although they probe only one vibrational 
signature at a time as there are no spectra obtained from the non-resonant 
background (Laing et al., 2017). 
The shortcomings associated with Raman spectroscopy outlined above have led not 
only to advancements in label-free Raman spectroscopy but also to the development 
of SERS, a highly sensitive advancement of conventional Raman spectroscopy. A 
variety of different metal surfaces can be used to provide surface-enhanced Raman 
but typically gold or silver surfaces which are plasmonic in nature are favored. This 
allows maximum electromagnetic enhancement due to the plasmonic coupling with 
the frequency of light used to excite the molecules being interrogated. Silver and 
gold can be used in a variety of different forms including electrodes, roughened 
metal films, vapor deposited films or very routinely as NPs. Silver or gold NPs are 
easily prepared through a metal reduction process which is scalable and controllable 
to give defined shapes and sizes of plasmonic NPs with degrees of enhancement 
that can be tuned to fit different laser excitations and also different surface 
chemistries. Most relevant to this review is the fact that they can be generated for 
use in vivo, functionalized with targeting molecules such as antibodies and tuned to 
work across a wide range of wavelengths from the visible to the near IR. SERS NPs 
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can be used in a multiplexed manner by incorporation of spectrally distinct reporter 
molecules into the NP (Raman reporters). These are often dyes that are carefully 
selected so that when the obtained spectra from multiple Raman reporters (and 
hence different NP conjugates) are overlaid, each distinct reporter/NP can be 
distinguished by a spectral peak (or peaks) unique to that particular reporter 
(Noonan et a., 2018). This also allows quantification of the signal based on the 
intensity of the peaks obtained following comparison with a reference standard and 
subtraction of the background signal from the medium/tissue. These unique 
properties have given rise to a number of potentially promising biological applications 
of SERS and the current use and future potential of SERS for imaging inflammation 
will be discussed in the following sections. 
Clinical use 
Raman spectroscopy/SERS are not yet clinically approved for the diagnosis or 
treatment of disease. To our knowledge, the only current clinical uses within the 
biological sciences is for real-time bacterial strain identification using commercially 
available Raman microscopes (Eberhardt et al., 2015) and an in vitro multiplex 
SERS-PCR assay for fungi identification (White et al., 2014). 
Pre-clinical use and in-human trials 
The major use for vibrational spectroscopy as a clinical diagnostic tool in immune 
disorders can be envisaged either as a tool for screening biological fluids or biopsy 
samples for disease specific molecular signatures or as a tool for in vivo imaging via 
molecular probes e.g. catheters introduced into vessels to monitor atherosclerotic 
plaque status or for monitoring the condition of the colon. Only the latter use will be 
discussed in this review and while progress is being made in developing vibrational 
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spectroscopy for imaging inflammatory diseases, vibrational techniques are still at 
the proof of concept stage of pre-clinical development. 
An area where vibrational spectroscopy might yield great clinical value is through 
integration of a Raman probe onto a catheter for intravascular use or for colonic 
examination of colitis and cancer. In 2005, Motz and colleagues developed an 
intravascular Raman probe for use on human patients. The first use of this 
intravascular Raman probe in humans was performed in 2006 on patients 
undergoing carotid endarterectomy and femoral artery bypass surgery. Quantitative 
characterization of the plaque stage was performed and compared with histological 
analysis of excised segments. Sensitivity and specificity of Raman detection was 
79% and 85% respectively (Motz et al., 2006). Advancing on this methodology was 
the creation of a multi-modal imaging catheter developed by Scepanovic et al., 2011. 
Here, the authors employed a similar approach to Motz and colleagues on patients 
undergoing carotid endarterectomy and femoral bypass surgery. The fiber optic 
catheter consisted of a combination of reflectance IR spectroscopy, fluorescence (to 
measure autofluorescence from plaque components) and Raman detection. Each of 
these modalities provides complimentary information on the biochemical composition 
of the lesion including detection of collagen, elastin, lipids, hemoglobin and calcium. 
This was the first demonstration of a triple multi-modal system acquiring spectra from 
a vessel wall in human patients. The authors then used the system on ex vivo artery 
sections and used the combined biochemical data to stratify the stage and 
complexity of the lesion with the data subsequently correlated with gold standard 
histology. The data obtained from the multi-modal probe showed a correlated 
sensitivity of 93% and specificity of 72% compared with histological classification 
(Scepanovic et al., 2011) which are very promising preliminary results. 
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SERS has had rather limited use in vivo with earlier studies demonstrating proof of 
principle that multiple spectrally distinct NPs can be detected in vivo (Qian et al., 
2008) and also one study demonstrated simultaneous detection of three distinct NPs 
targeted to 3 tumor biomarkers following direct injection into a mouse tumor (Dinish 
et al., 2014), an important stepping stone to the in vivo multiplexed use of SERS. 
Our laboratory has been working to developing SERS as a multiplexing in vivo 
imaging tool for detection of vascular inflammation. In our first series of experiments, 
we were able to demonstrate that Pegylated NPs conjugated to an anti -ICAM-1 
antibody could be employed to detect ICAM-1 expression on aortic sinus tissue 
sections from apoE-/- mice with a signal to noise ratio greater than that produced by 
immunofluorescence (McQueenie et al., 2012). We also supplemented this data with 
in vivo experiments using an intradermal inflammatory challenge model (LPS) in the 
ear pinna. LPS upregulates ICAM-1 expression in the ear vasculature and 24h 
following LPS administration, FITC conjugated anti-ICAM-1 antibodies or anti-ICAM-
1 functionalized SERS NPs were intravenously injected and non-invasively imaged 
by either two-photon fluorescence microscopy or SERS 30 minutes later. Both 
techniques detected upregulated ICAM-1 expression on blood vessel walls relative 
to isotype but as per the ex vivo studies, SERS showed superior sensitivity of 
detection (McQueenie et al., 2012). Recently, Gold Nanorods were deployed as 
SERS probes for the detection of adhesion molecules on inflamed macrophages 
(Pissuwan and Hattori, 2017). More recently we have utilized a SERS based system 
for the multiplex detection of VCAM-1, ICAM-1 and P-selectin on activated human 
macrophages and endothelial cells, human arterial and venous samples and a novel 
in-house developed in vivo model (Human adipose engraftment mouse model 
(HANSG)) that allows us to maintain viable human vascularized adipose tissue 
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implants in an immunocompromised mouse (NSG mouse) in which we can test our 
SERS functionalized NPs (targeted to human specific inflammatory molecules) 
against our 3 inflammatory targets on human vessels in vivo following intravenous 
injection (Noonan et al., 2018). In this work, we successfully obtained SERS 
spectroscopy and microscopy data from cultured inflammed endothelial cells, human 
arterial segments and most importantly from non-invasive SERS spectral analysis of 
adhesion molecules present within mice containing the transplanted human tissue 
following inflammatory challenge (Figure 5). We have therefore demonstrated the 
feasibility of using the SERS-NP platform for simultaneous targeted multiplex 
detection of adhesion molecules in vivo. Adhesion molecules have been utilized in 
previous molecular imaging studies using established techniques such as PET and 
MRI; however, these studies predominantly explored single target molecule 
detection (McAteer et al., 2008; Nahrendorf et al., 2009; Broisat et al., 2012; 
Dimastromatteo et al., 2013). Recent advances have shown that the simultaneous 
identification and discrimination of 24 parameters is possible in vitro using an SRS 
approach (Wei et al., 2017) which makes extending the multiplexing potential of 
SERS in vivo a distinct possibility in the very near future thus allowing a more 
detailed interrogation of the molecular events that differentiate diseased from healthy 
tissue. 
Endoscopic probes utilizing SERS NPs targeted to known cancer molecules on the 
luminal surface of the colon have been developed in tandem with fiber-optic Raman 
endoscopes for SERS detection of cancerous and pre-cancerous lesions. The most 
significant advance in this field is the creation of a human compatible, flexible Raman 
fiber optic device that can be used in the GI tract. It is a non-contact device and 
when applied in the colon has a working distance up to 25 mm from the colon wall. 
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The device is also highly sensitive, being able to detect targeted NPs only sparsely 
bound to colonic wall cells (~240 NPs per cell) (Garai et al., 2015). It has also been 
demonstrated in similar studies that superficially introduced NPs into the colon do 
not pass over into the systemic circulation, even after 3 days and indeed most are 
naturally excreted within 24 hours (Thakor et al., 2011), thus eliminating any 
potential off-site exposure. Assessing studies that have utilized either fluorescent or 
SERS NPs for detection of biomarkers using endoscope techniques has 
demonstrated to date a detection sensitivity of <1 fM for SERS compared with =>10 
fM for fluorescence-based methods. Therefore, SERS offers not only superior 
sensitivity but also the ability to multiplex a greater number of markers using a single 
monochromatic laser (Laing et al., 2017). 
Theranostics 
As introduced in section 2.4, photothermal therapy utilizing NP size agents can offer 
a viable method for inducing cell death. NP designs including single-walled carbon 
nanotubes (SWNTs) and gold nanorods are particularly effective in inducing cell 
death in vivo (Dickerson et al., 2008; Chakravarty et al., 2008; von Maltzahn et al., 
2009). While these studies were oncology focused, SWNTs are also readily uptaken 
by macrophages in carotid arteries in mice following carotid ligation. Following 
exposure of excised arteries to NIR laser excitation, macrophages engulfing SWNTs 
undergo photothermal cell death (Kosuge et al., 2012). The induction of apoptosis 
only following targeted excitation with NIR light provides a high level of specificity in 
targeting only lesion resident macrophages. Further refinements of photothermal 
therapy may include the use of multi-modal NPs to guide photothermal therapy and 
monitor outcomes. Gao and colleagues developed a gold NP (nanostar configuration 
that is highly amenable to heat absorption and with high sensitivity of detection (1 
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fM) that was surrounded with Gd chelates making the particle amenable to both 
SERS and MRI and with no observed toxicity out to 30 days following administration 
in mice (Gao et al., 2015). Remarkably, photothermal NP therapy has already been 
trialed in human atherosclerotic patients in the Plasmonic Nanophotothermal 
Therapy of Atherosclerosis trial (NANOM-FIM; ClinicalTrials.Gov identifier: 
NCT01270139) performed between 2007 and 2012. The combination of 
intravascular or transcutaneous NIR laser excitation with macrophage targeted NPs 
resulted in a reduction in total plaque volume, no adverse events throughout the 1 
year follow up and increased survival in the treatment group (Kharlamov et al., 
2015). 
Another therapeutic avenue where SERS could be implemented is for delivery of 
anti-inflammatory drugs to the site of pathology and subsequent monitoring of drug 
release. The use of NP-drug conjugates that emit contrasting optical signatures pre- 
and post-drug release that can be detected by SERS offers the potential for 
measuring drug release under acidic pH conditions, such as found in lysosomes 
where internalized drug-NP conjugates are trafficked to following endothelial cell 
adhesion molecule targeting (Ricard et al., 1998; Muro et al., 2003; Kelly et al., 2005; 
Serrano et al., 2012). SERS-functionalized gold NPs carrying pH triggered 
doxorubicin release have successfully been targeted to cancer cells and drug 
delivery was confirmed by SERS tracking (Song et al., 2012). A similar method 
employing doxorubicin conjugated to gold NPs via a pH sensitive hydrazine linker 
was employed to also target doxorubicin to cancer cells (Kang et al., 2013). Such an 
approach has not yet been applied to vascular endothelial cells or to deliver anti-
inflammatory drugs but the utility of SERS sensitive NPs in such a context creates a 
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potent dual-modality tool for both delivering and tracking therapeutic compounds to 
inflammatory sites. 
Advantages and barriers to clinical translation 
Raman probes either alone or on multi-modal catheters can map the biochemistry of 
the plaque with good sensitivity and specificity. The system created by Motz et al., 
2005 was the first real-time imaging system for measuring Raman spectra 
intravascularly. In those studies, the entire duration of spectral acquisition, data 
processing and diagnostic read out was less than 5s, although the in vivo acquisition 
was less than 1s. One limitation of the Raman probe used by Motz et al. (2006) and 
the multi-modal system used by Scepanovic et al. (2011) is that they don’t provide a 
real-time image of the vessel wall in the way that IVUS and OCT do. Therefore, the 
goal would be to combine a fast high resolution real-time imaging technique such as 
OCT (which can pinpoint areas interest) with Raman or a multi-modal system which 
can acquire the detailed molecular information. This would yield a highly powerful 
tool for investigating intravascular or colonic pathologies. 
SERS is still at an early stage of development in terms of application to in vivo 
imaging, yet it has a number of strengths that may address the limitations of current 
imaging modalities. These can be outlined as follows: 
1) Fast acquisition times; 2) high sensitivity, (enhancement over Raman can be as 
much as 1010-1011) and even higher when the laser frequency is in resonance with 
the SERS molecule (McNay et al., 2011; Guerrini and Graham, 2012); 3) Low toxicity 
of AuNPs in animal models and early human trials; 4) Not susceptible to 
photobleaching; 5) Deep tissue imaging possible (up to 5cm reported by Asiala et al., 
2017); 6) Compatible with a broad range of fluorophores in the NIR window; 7) 
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Multiple Raman reporters can be excited at a single wavelength; 8) Narrow emission 
spectrum allow accurate deconvolution of the data and high multiplexing; 9) Portable 
systems now available expanding the use beyond specialized research labs; 10) 
NPs can be configured for theranostic use such as photothermal therapy or as a site 
specific drug release vehicle. 
In terms of barriers to translation, the ability to accurately deconvolute spectral data 
is a key requirement for all forms of vibrational spectroscopy. As the complexity of 
the sample matrix increases, more sophisticated mathematical and statistical data 
analysis routines are required to provide clear and concise data from the data-rich 
spectroscopic signals. The quantification of Raman and SERS data is a rapidly 
progressing area of research with highly promising results indicating SERS spectra 
can be quantified accurately using multiple mathematical models including Bayesian 
modeling (Zhong et al., 2011) which we have successfully demonstrated shows a 
linear increase in proportion to increasing NP concentration (Noonan et al., 2018). 
When aiming for the use of SERS NPs in human patients, the toxicity of the NPs 
must be accurately known including their residence times and fate within the patient 
(Cicha et al., 2018). Studies will need to address where SERS NPs accumulate, how 
this relates to NP size, shape and functionalization and any possible degradation 
prior to excretion. Gold per se is not a toxic metal and has been used in medicines 
for many years, for example gold based compounds are used to treat RA (Alkilany 
and Murphy, 2010); however, the toxic status of nanoscale gold particles remains 
obscure with differential toxic effects found in cellular and animal models depending 
on size, shape, charge, shell material and dose of NPs administered (Gerber et al., 
2013; Fratoddi et al., 2015). Shell material such as PEG has shown to be 
biocompatible and displays very low toxicity in human patients (Alexander et al., 
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2013), being used in many pharmaceutical formulations around the world to improve 
drug residence times. PEG also reduces the toxicity of the NP by encapsulating the 
gold thus bare gold is not freely available in the circulation as well as acting as an 
anchor for conjugating targeting antibodies or peptides. Despite mixed pre-clinical 
results to date regarding the toxicity of NPs, silica-gold pegylated NPs have 
progressed to human clinical trials for thermal ablation of cancer (Stern et al., 2016). 
A safety evaluation trial in 22 prostate cancer patients who were administered an 
intravenous infusion of ‘Aurolase’ NPs and monitored for 6 months revealed only 2 
minor adverse events related to the therapy. Interestingly and importantly, the FDA 
classified those NPs as a medical device rather than a drug (Stern et al., 2016) 
which reduces the time to regulatory approval. Multi-modal SERS NPs are also 
being developed. In an excellent study by Dinish et al., 2015, the authors created 
targeted NPs containing a NIR dye detectable by both SERS and photoacoustics in 
an in vivo mouse tumor model at a depth of several cm and at µM resolution allowing 
precision location of the tumor. The authors noted an accumulation of NPs in the 
liver and spleen but were cleared within 72h, which is encouraging in terms of a lack 
of organ retention (Dinish et al., 2015). More generally the creation of multi-modal 
SERS probes combined with modalities that offer visualization of tissue will greatly 
facilitate the location and optimum time point to initiate SERS data acquisition. To 
conclude our discussion on SERS, it is clear that SERS has many intrinsic 
advantages that may meet clinical needs currently unserved by classical imaging 
modalities, yet it will require substantial investment of resources across multiple 
disciplines to determine if these inherent advantages can be translated to a clinically 
useful imaging modality. 
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Figure 5. In vivo SERS-BFNP molecular imaging of adhesion molecules. 
Following engraftment of human adipose, HANSG mice were allowed to recover for 3 
weeks. Mice were then injected intravenously with 5 μg of human recombinant TNF-
α 4 h prior to receiving an intravenous injection of BFNP. (A) Following SERS-BFNP 
molecular imaging, adipose grafts were excised and immunofluorescently stained for 
human (red) and murine (green) CD31. (B) Isotype control, ICAM-1, VCAM-1, and P-
selectin staining are also shown in white counterstained with human CD31 (red). 
Nuclei were counterstained using Hoechst 33342 (blue). (C) To conduct SERS-
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SERS microscopy. Supporting previous studies using 
BFNP as drug delivery systems [36,37], it was found 
that ICAM-1-targeted particles were internalized by 
CAECs, resulting in amplification of the SERS signal 
and presenting a mechanism that could be 
manipulated for theranostic drug delivery or 
improving imaging depth. 
 
 
Figure 4. In vivo SERS-BFNP molecular imaging of adhesion molecules. Following engraftment of human adipose, HANSG mice were allowed to recover for 
3 weeks. Mice were then injected intravenously with 5 μg of human recombinant TNF-α 4 h prior to receiving an intravenous injection of BFNP. (A) Following 
SERS-BFNP molecular imaging, adipose grafts were excised and immunofluorescently stained for human (red) and murine (green) CD31. (B) Isotype control, 
ICAM-1, VCAM-1, and P-selectin staining are also shown in white counterstained with human CD31 (red). Nuclei were counterstained using Hoechst 33342 (blue). 
(C) To conduct SERS-BFNP molecular imaging, HANSG mice were anaesthetized and their adipose grafts non-invasively analyzed in vivo using SERS spectroscopy. (D) 
SERS spectra were acquired from mice that received a mixture of isotype-PPY, -BPE and -PYOT (blue spectra), or anti-P-selectin-PPY, anti-ICAM-1-BPE, 
anti-VCAM-1-PYOT BFNP (red spectra). The spectra shown are from 5 isotype vs. 5 targeted mice, with each spectrum acquired from a different mouse. (E) In 
addition to immunofluorescence microscopy, excised adipose grafts were analyzed using SERS microscopy. Detection of BFNP from sections of adipose tissue 
isolated from HANSG mice that received anti-ICAM-1 (purple), anti-VCAM-1 (red), and anti-P-selectin (blue) (upper panels) or Isotype-BPE (purple), Isotype-PYOT 
(red), and Isotype-PPY (blue) (lower panels) are shown superimposed on darkfield tissue images alongside a magnified image of Raman maps from the scanned areas 
(black boxes). The colored circles in the Raman map ((E) upper panel) correlate to the acquired spectra shown in (F) above their respective reference spectra. The 
optical image in (E) is a darkfield image. Scale bars: (A) = 1000 μm; (B) = 100 μm; (E) = 20 μm. 
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BFNP molecular imaging, HANSG mice were anaesthetized and their adipose grafts 
non-invasively analyzed in vivo using SERS spectroscopy. (D) SERS spectra were 
acquired from mice that received a mixture of isotype-PPY, -BPE and -PYOT (blue 
spectra), or anti-P-selectin-PPY, anti-ICAM-1-BPE, anti-VCAM-1-PYOT BFNP (red 
spectra). The spectra shown are from 5 isotype vs. 5 targeted mice, with each 
spectrum acquired from a different mouse. (E) In addition to immunofluorescence 
microscopy, excised adipose grafts were analyzed using SERS microscopy. 
Detection of BFNP from sections of adipose tissue isolated from HANSG mice that 
received anti-ICAM-1 (purple), anti-VCAM-1 (red), and anti-P-selectin (blue) (upper 
panels) or Isotype-BPE (purple), Isotype-PYOT (red), and Isotype-PPY (blue) (lower 
panels) are shown superimposed on darkfield tissue images alongside a magnified 
image of Raman maps from the scanned areas (black boxes). The colored circles in 
the Raman map ((E) upper panel) correlate to the acquired spectra shown in (F) 
above their respective reference spectra. The optical image in (E) is a darkfield 
image. Scale bars: (A) = 1000 μm; (B) = 100 μm; (E) = 20 μm. Figure and figure 
legend reprinted from Noonan et al. In vivo multiplex molecular imaging of vascular 
inflammation using surface-enhanced Raman spectroscopy. Theranostics. 
2018;8:6195-6209. Distributed under the terms of a Creative Commons Attribution 
(CC BY) license (https://creativecommons.org/licenses/by/4.0/). 
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2.10 Summary table of molecular imaging modalities 
Modality Resolution Sensitivity 
(mol/L) 
Depth Strengths Limitations Stage of 
development 
CT 15-50 μm 10
-2
-10
-3
 Body-
wide 
Non-invasive, fast 
imaging,  
good spatial 
resolution 
Low sensitivity, 
radiation exposure, 
poor soft tissue 
contrast, limited 
multiplexing 
Clinical (pre-
clinical for sub 
mm 
resolutions) 
MRI 0.5-1.5mm 
(1.5T) 
10-200 µm 
(>3T) 
10
-3
-10
-5
 Body-
wide 
Good spatial 
resolution, non-
invasive, high soft 
tissue contrast, no 
radiation 
exposure, low 
toxicity tracers with 
some already 
clinically used 
Poor sensitivity, long 
imaging times often 
required, poor signal 
to noise ratio, lack of 
multiplexing outside 
of specialist CEST 
MRI. 
T1/T2 
(clinical). 
Other forms 
pre-
clinical/clinical 
trials 
MPI ~0.5mm * 
(proportional 
to field 
strength) 
10
-6
 to 10
-8 
* Body-
wide 
Fast real-time 
imaging, Good 
signal to noise, 
higher sensitivity 
than MRI, can 
utilize established 
MRI contrast 
agents, no 
radiation 
exposure, 
quantifiable 
Limited in vivo data, 
sensitivity is unlikely 
to match 
PET/SPECT, no 
anatomic 
information, no 
multiplexing  
Pre-clinical 
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PET 4-6mm 
(clinical) 
1-2mm (pre-
clinical) 
10
-11
-10
-12
 Body-
wide 
Non-invasive, high 
sensitivity, clinical 
grade scanners 
well established 
Poor spatial 
resolution, radiation 
exposure, high cost, 
short half-life of 
radionucleotides 
requires on-site 
cyclotron, no 
anatomic detail 
without hybrid 
CT/MRI, no 
multiplexing 
Clinical 
SPECT 0.5-2 mm 10
-10
-10
-11
 Body-
wide 
Non-invasive, high 
sensitivity, 
cheaper than PET 
and more widely 
available 
Poor spatial 
resolution, radiation 
exposure, no 
anatomic detail 
without hybrid 
CT/MRI, very limited 
multiplexing 
capacity 
Clinical 
CEUS 50-500 µm Not well 
defined.  
In vivo 
estimates 
are 10
-6 
to 
10
-9
 
Body-
wide 
Low cost, good 
sensitivity, no 
radiation 
exposure, 
anatomic and 
molecular 
information in a 
single scan, high 
speed real-time 
imaging, amenable 
Signal to noise ratio 
can be poor, lack of 
vascular penetration 
confines 
microbubble 
approaches to 
vascular molecules, 
no multiplexing 
Clinical (pre-
clinical/clinical 
trials for 
targeted 
CEUS) 
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to bedside testing, 
microbubble 
contrast agents 
are clinically 
approved, can be 
used on catheters 
for invasive 
imaging, potential 
to act as a drug 
delivery 
theranostic tool 
NIRF 10 µM-2mm 
(depending 
on depth and 
tissue type) 
10-
10
 to 10-
11
 
<2cm High spatial 
resolution at 
shallow depths, 
high sensitivity, no 
radiation 
exposure, 
relatively low cost, 
multiplexing, can 
be used on 
catheters for 
invasive imaging 
Imaging restricted to 
superficial structures 
or via surgical 
exposure, potential 
toxicity of pre-
clinical tracers, 
multiplexing ability is 
poor compared with 
vibrational 
spectroscopy 
Clinical 
(anatomic 
using ICG) 
Pre-clinical 
(targeted 
NIRF) 
PAI/MSO
T 
<50 µM to 
several 
hundred µM 
(depth 
dependent) 
<10
12
 <5-6 cms High sensitivity, no 
radiation 
exposure, superior 
penetration depths 
compared with 
other optical 
modalities, low 
Poor penetration 
depths when 
compared with 
current clinical 
imaging modalities, 
tracers not approved 
for human use, Data 
Pre-clinical 
(Early clinical 
trials) 
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cost, anatomic and 
molecular 
information in a 
single scan, high 
speed real-time 
imaging, can be 
used on catheters 
for invasive 
imaging, 
multiplexing with 
MSOT, potential to 
act as a drug 
delivery 
theranostic tool 
acquisition and 
processing still to be 
optimized, less 
multiplexing 
capacity than 
vibrational 
spectroscopy 
Raman 
spectros
copy 
<1 µM to 
several 
hundred µMs 
 ~10
-5
 to 10
-6
 
for analytes 
in solution * 
Several 
mms 
Label free 
analysis, 
low cost, portable,  
real-time or near 
real-time imaging, 
high spatial 
resolution, able to 
discriminate a 
wide set of 
molecular 
structures, can be 
used on catheters 
for invasive 
imaging 
Low sensitivity 
leading to long 
imaging times, poor 
imaging depths 
restricting use to ex 
vivo or catheter 
probes, requires 
complex 
chemometric 
analysis to separate 
analytes from 
spectra 
Pre-clinical 
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SERS <100 nm to 
several µM 
10-
11 
to 10-
14
 Up to 5 
cms with 
SESORS 
High sensitivity, 
utilizes gold NPs 
that display low 
toxicity, fast 
imaging times, no 
photobleaching, 
can utilize a broad 
range of existing 
dyes for 
multiplexing, deep 
tissue imaging 
possible with 
SESORS, portable 
hand held devices 
now available,  
SERS NPs can be 
tuned for 
photothermal 
therapy or targeted 
drug release 
Spectra can be 
sensitive to changes 
in NP orientation 
and interference 
from adjacent 
structures, tracers 
not approved for 
human use, 
complex statistical 
algorithms are 
required for 
separation and 
quantification of 
multiplexed spectra 
Pre-clinical  
* Based on a very small number of published values 
 
3. Summary and conclusions 
To summarize, an ideal molecular imaging modality (either alone or as a hybrid with 
another) should possess high sensitivity and spatial resolution, fast imaging times, 
be able to image structures at depth within the body (unless utilized solely as an 
invasive catheter), be quantifiable and reproducible, have low economic burden and 
have the ability to assess multiple targets in a single scan. For successful clinical 
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translation, short imaging times, patient comfort, accuracy, reproducibility, 
invasiveness of the procedure and necessity for hospitalization should be carefully 
considered. Highly specialized imaging modalities create an additional barrier by 
requiring trained reporting staff, thus wider application is easier with more 
approachable methods, such as US. 
In a world where medical authorities and institutions demand greater value for 
money, systems that can be brought to clinical specifications with less regulatory 
hurdles are going to be highly prized. Of the current clinical modalities, CEUS and 
MRI may compete as safe, cost-effective molecular and theranostic imaging tools, 
with similar capabilities and limitations. CEUS with more extensive use of 
microbubble contrast agents and targeted microbubbles now in clinical trials is 
further on this development path than MRI, although as 19F MRI progresses into 
human use, only then will it be possible to judge the respective merits of these two 
modalities as potential molecular imaging tools that bring added diagnostic value 
over current systems. There appears little enthusiasm to move PET to clinical 
targeted imaging of disease biomarkers beyond oncology, but this may not be a 
permanent restriction. However, PET/SPECT will always be constrained by radiation 
exposure and the lack of multiplexing. The potential for clinical molecular imaging of 
emerging technologies is even harder to judge with any certainty given the scarcity 
of in-human (and even pre-clinical when it comes to the most recent technologies 
such as MPI and SERS) testing and the lack of completed clinical trials. We would 
suspect PAI will accelerate quicker than the other pre-clinical modalities and there is 
much hope within the pre-clinical academic community that it can translate to a 
clinical molecular imaging device. The application of SERS in vivo is just beginning 
to be realized with only a handful of publications in this area hence the technology is 
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very early stage. However, its powerful set of attributes will continue to be tested in 
animal models and human tissue samples to build the robust, standardized 
quantification models that are necessary to make datasets consistent and 
comparable thus allowing progression to more rigorous diagnostic testing trials. We 
believe that the next decade will be key for all forms of vibrational spectroscopy in 
demonstrating whether they have a place in the clinic. 
Major barriers to clinical translation of a molecular imaging modality include safety, 
cost, overcoming technological hurdles in signal acquisition and processing and 
performance versus established technologies/clinical utility (Table 5). As demands 
on healthcare services increase, then the cost of implementing new technologies has 
to have a high threshold of clinical value. Although development costs are cheaper 
for a diagnostic imaging agent, costs are still substantial due to the lengthy 
development process because regulatory authorities treat molecular imaging agents 
as they would any other drug. An advantage of PET tracer development in the US - 
due to their trace amount administered dose - is that an exploratory investigative 
new drug application (eIND) pathway is available which reduces the time between 
pre-clinical and first in-human trials due to less stringent requirements for pre-clinical 
animal testing (Abou-Elkacem et al., 2015). This pathway is not open to other novel 
contrast agents such as targeted microbubbles or metallic NPs (Cicha et al., 2018). 
However, it is quite conceivable that as regulatory authorities become more 
convinced of the general safety of a contrast agent then expedited routes to clinical 
testing may be available if only the targeting ligand is changed on an otherwise 
previously tested safe contrast agent. Validation of this is emerging in CEUS with the 
KDR targeted microbubble used in a clinical trial in breast cancer showing excellent 
patient tolerability, comparable with a similar non-targeted microbubble. It is also 
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interesting to note that the FDA classified the first pegylated gold NP therapeutic 
agent (Aurolase) as a medical device rather than a drug, reducing the burden and 
time towards regulatory approval. Whether this will remain the case for targeted gold 
NPs, such as those utilized in SERS or PAI is unclear as regulatory approval has not 
been granted for these imaging agents. At present, photoacoustic studies in humans 
rely on endogenous contrast agents or approved fluorescent molecules such as ICG 
(Valluru et al., 2016). Regardless, the lack of observed adverse events in patients 
treated with Aurolase could be a key milestone in the subsequent translation of 
metallic NP based agents into further human trials based around diagnostic imaging.  
When considering costs, it is also important to keep in mind what the primary goal of 
molecular imaging is, namely to identify disease at an early stage or better predict its 
evolution and to monitor response to therapeutics. In this regard, clinicians require 
more robust integrated patient data that may include patient history, clinical scores, 
serum biomarkers and real-time, high resolution molecular imaging that can not only 
add clinical value, but better inform on the underlying cellular and molecular 
mechanisms in a patient-specific manner. The current inability to quantify individual 
disease progression in inflammatory conditions impairs our therapeutic choices and 
prevents personalized medicine. Our current approach to capture inflammatory 
processes is outdated, cumbersome and poses a substantial clinical limitation to 
precision medicine. Therefore, molecular imaging has the potential to bring many 
benefits to the clinic including improved patient outcomes, reduced diagnostic costs, 
reduced physical and emotional burden on patients and further cost savings to 
Health Authorities via the reduced demand for surgery and ineffective treatments 
due to improved decision making arising from the results of molecular imaging. 
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Table 5. Barriers to Clinical Translation 
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Cost Safety Technology Clinical value 
 Research 
 Upscaling from 
animals to human 
 Clinical trials 
 In-clinic cost 
 
 Tracer properties 
(dose, radiation, 
heavy metal, tissue 
accumulation) 
 Modality (magnetic 
field, laser, acoustic 
energy) 
 Exposure limits may 
limit exploratory use 
 
 Does not conform to 
expectations 
 Pre-clinical devices not 
compatible/modifiable to 
clinical specifications 
 Designed for a single 
anatomic site 
 Quantification/standardiz
ation 
 
 Minimal advance in 
biological data 
 Poor performance in 
other areas (e.g. 
oncology) 
 Insufficient 
improvement over 
established methods 
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